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Soon after viruses enter the cell, they encounter host innate and adaptive 
immune responses that must be evaded. Restriction factors are proteins from the 
host innate immune response that impair the establishment of viral infection. 
Primate lentiviruses encode “accessory” proteins, which are not required 
for viral replication but essential to counteract host restriction factors. The 
primate lentivirus accessory proteins are Nef, Vif, Vpu, Vpr, and Vpx. The main 
mechanism used by these proteins to counteract restriction factors is the 
manipulation of the ubiquitin proteasome system. While Vpu usurps Cul1, Vpr 
and Vpx hijack Cul4A by associating with DCAF1.  
Through interaction with DCAF1, Vpx degrades SAMHD1, a protein that 
impairs viral reverse transcription in myeloid cell lineages. Vpr, on the other 
hand, induces poly-ubiquitination of Mus81 to activate the endonuclease complex 
SLX4com. SLX4com activation was suggested to induce cell cycle arrest in 
G2/M. SIVagm Vpr is homologous to HIV-1 Vpr in sequence and structure, but 
these two proteins have important functional differences. Unlike HIV-1 Vpr, 
SIVagm Vpr degrades SAMHD1 and induces G2 arrest but in a species-specific 
manner. In this work, we generated chimeric proteins between HIV-1 Vpr and 
SIVagm Vpr, in order to understand the structure-function relationships in these 
proteins. We showed a de novo ability to arrest cell cycle in human cells when 
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the C-terminus of HIV-1 Vpr was grafted onto SIVagm Vpr. Using point mutants 
of HIV-1 Vpr, we were able to uncouple degradation of Mus81 from cell cycle 
arrest, suggesting that these two functions are independent. 
To study the amino acid residues of DCAF1 that are responsible for 
interactions with Vpr and Vpx, we generated a large array of point mutants. We 
demonstrated that Vpr and Vpx interact with DCAF1 using a similar region on 
DCAF1, but establishing interactions with different residues.  
We then used an inhibitor of the Neddylation pathway (MLN4924) to 
examine the role of CRUL in the abilities of accessory proteins to target host cell 
proteins. Our results demonstrate that inhibition of CRUL with MLN4924 did not 
affect downregulation of tetherin, suggesting that the trans-golgi entrapment is 
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HIV/SIV Accessory Proteins and Cellular Restriction Factors 
HIV-1 virus, the causative agent of AIDS (Barre-Sinoussi et al., 1983) a 
disease characterized by gradual suppression of the immune response, is an 
extremely pathogenic lentiviral responsible for the death of millions of people 
around the world.  In 2013, 35 million people were living with HIV worldwide 
(WHO as of December, 2014). Although ART (Antiretroviral Therapy) is been 
used to control viral replication, slowing the progression to AIDS and decreasing 
the mortality rate, a cure is still not available. In 2013, around 1.5 million people 
died from AIDS (WHO as of December, 2014). Despite all the research on HIV-1, 
much remains to be learned. 
HIV-1 is comprised of a small genome (around 10kb) and encodes for 9 
genes. gag, pol, and env encode for structural proteins; tat and rev for regulatory 
proteins and nef, vif, vpu, vpr, and/or vpx (HIV-2/SIV) for accessory proteins. 
While structural and regulatory proteins are important for HIV-1 entry, reverse 
transcription, integration, and assembly, accessory proteins are required to 
evade antiviral immune response. 
The viral infectivity factor (Vif) is a late gene product and is required for 
production of infectious particles. Its name came from observations where 
specific cell lines, were permissive for replication with Vif-deficient viruses, while 
in other cell lines the replication was blocked (Gabuzda et al., 1992). It was later 
reported that the nonpermissiveness effect was due to expression in these cell 
lines of a restriction factor called Apolipoprotein B mRNA-editing enzyme 3G 
(APOBEC3G) (Madani and Kabat, 1998; Sheehy et al., 2003). The host protein 
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APOBEC3G is a cytidine deaminase that functions during reverse transcription of 
the viral genome. APOBEC3G deaminates cytidine residues, converting them to 
uridine. When RT synthesizes the plus sense DNA strand, then the above 
chemical change results in an adenosine substitution in place of guanine. This, 
when repeated multiple times, will result in hypermutation and inactivation of the 
viral genome (reviewed in Feng et al., 2014). To inhibit this restriction, Vif 
functions as an adaptor molecule for the cullin-5 E3 ubiquitin ligase (Yu et al., 
2003). By interacting with Cul5, via Elongin B/C (Elo B/C) subunits, Vif displaces 
the endogenous substrate and recruits APOBEC3G for ubiquitination and 
subsequent proteasomal degradation (Yu et al., 2003).   
Viral protein-unique (Vpu) has this name because it is found only in HIV-1 
but not in HIV-2. Vpu has numerous functions during progression of HIV-1 
infection that range from downregulation of CD4 from the cellular membrane 
(Levesque et al., 2003), a process that involves the cullin RING ubiquitin ligase 
(CRUL) cullin-1 and the UPS (Margottin et al., 1998), to downmodulation of 
CCR7 (Ramirez et al., 2014), CD1d (Moll et al., 2010), BST-2/Tetherin (Van 
Damme et al., 2008), MHC-II (Hussain et al., 2008), and NTB-A (Shah et al., 
2010). BST-2 is a transmembrane protein that inhibits nascent virus release from 
the infected cell. Vpu overcomes this restriction by downregulating and degrading 
BST-2/tetherin, a process that occurs independently of the CRULs. Because Vpu 
is absent in HIV-2 and SIV, downregulation of BST-2/tetherin occurs through the 
Env glycoprotein and Nef protein in these lentiviruses, respectively. The 
mechanism used by Vpu to downregulate BST-2/tetherin is still controversial. 
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While some studies suggest that this effect occurs through degradation by the 
UPS, our group (Ramirez et al. submitted for publication) and others suggest that 
downregulation of BST-2/tetherin from the cell surface is independent of the 
UPS.  We showed that inhibition of CRULs function abrogates the ability of Vpu 
to downregulate CD4 from the cell surface but not BST-2/tetherin (Ramirez et al. 
manuscript submitted for publication), suggesting the effect of Vpu in BST-
2/tetherin is independent of the CRULs. 
While myeloid cell lineages and resting CD4+ T-cells are able to restrict 
HIV-1 infection, the same is not true for HIV-2 and SIV (Ayinde et al., 2010; 
Yamashita and Emerman, 2006). The underlying reason for this difference is that 
HIV-2 and SIV encode for a common protein called Viral protein X (Vpx) 
(Laguette et al., 2011). Myeloid cells and resting CD4+ T-cells express the sterile 
alpha motif (SAM) and histidine/aspartic acid domain (HD) containing protein 1 
(SAMHD1), which is responsible for inhibition of HIV-1 infection (Hrecka et al., 
2011; Laguette et al., 2011). SAMHD1 is a deoxynucleoside triphosphate 
triphosphohydrolase that hydrolyzes dNTP to a deoxynucleoside and inorganic 
triphosphate (Goldstone et al., 2011). Through this function, SAMHD1 decreases 
the level of available intracellular pool of dNTPs, impairing viral reverse-
transcription (Amie et al., 2013; Goldstone et al., 2011; Kim et al., 2012; 
Srivastava et al., 2008). Like other lentiviral accessory proteins, Vpx uses the 
Cul4DDB1/DCAF1ubiquitin E3 ligase to overcome SAMHD1 restriction (Srivastava et 
al., 2008). Vpx manipulates this E3 ligase through direct interaction with the 
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adaptor protein DCAF1 (VprBP) (Hrecka et al., 2011; Srivastava et al., 2008) to 
induce SAMHD1 ubiquitination and degradation.  
The viral protein R (Vpr) is a paralog of Vpx and also manipulates the UPS 
by hijacking the cellular Cul4DDB1/DCAF1 ubiquitin E3 ligase.  Vpr is known to 
induce, among other functions, cell cycle arrest in G2-to-M transition, a process 
that requires interaction with DCAF1. Although several host proteins have been 
described to interact with Vpr, only in the beginning of 2014 was the SLX4 
complex found to be targeted by Vpr to induce cell cycle arrest (Laguette et al., 
2014). In contrast to what was expected, the SLX4comp was shown to be 
activated, instead of degraded, by Vpr. However, the exact mechanism by which 
this occurs and the reason why the virus induces cell cycle arrest remain to be 
understood. This chapter will focus on Vpr, its reported targets, and the most 
accepted molecular mechanism used by this accessory protein to arrest cell 
cycle. A detailed understanding of restriction factors and how HIV-1 evades their 
recognition will be crucial for novel drug development. 
 
Vpr: The Enigmatic Multifunctional Protein  
The accessory protein Vpr is a 14KDa protein that is conserved among 
primate lentiviruses, being found in HIV-1, HIV-2, and in SIV (Hattori et al., 1990; 
Ogawa et al 1989; Tristem et al., 1992). Because it is highly conserved through 
the evolution, it is believed that Vpr is extremely important for HIV pathogenesis 
(Emerman, 1996; Planelles et al., 1996; Stivahtis et al., 1997). NMR (nuclear 
magnetic resonance) studies of HIV-1 Vpr demonstrated that this protein is 
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comprised of a core of three alpha helices connected by flexible loops, flanked by 
amino- and carboxy-terminal unstructured regions (Figure 1.1) (Morellet et al., 
2003). Initially, experiments in rhesus macaques demonstrated that, when the 
macaque was infected with SIVmac carrying a mutated Vpr, disease progression 
and viral replication were delayed, revealing the importance of Vpr in vivo (Hoch 
et al., 1995; Lang et al., 1993). Vpr is packaged into the virions, by direct 
interaction with the p6 region of Gag (Bachand et al., 1999; Paillart and 
Gottlinger, 1999; Selig et al., 1999) and is released upon viral entry into the cells, 
suggesting that Vpr is required for the early steps of viral infection (reviewed in 
Guenzel et al., 2014). Several functions were attributed to Vpr during the virus 
life cycle; among them are: induction of cell cycle arrest in G2 phase, apoptosis, 
nuclear import of the preintegration complex, transactivation of the viral promoter, 
and increase in the fidelity of the reverse transcription (reviewed in Dehart and 
Planelles, 2008; Le Rouzic and Benichou, 2005). The most extensively studied 
characteristic of Vpr is the capacity to induce G2 arrest, a function that is also 
conserved among Vpr from primate lentiviruses (Planelles et al., 1996). 
 
Vpr and Its Mechanism of Induction of G2 Arrest 
Induction of G2 arrest by Vpr was first reported in 1995 (He et al., 1995; 
Jowett et al., 1995; Re et al., 1995; Rogel et al., 1995). The cell cycle arrest 
induced by Vpr is similar to that observed as consequence of DNA damage and 
replication stress (He et al., 1995; Jowett et al., 1995; Re et al., 1995; Rogel et 
al., 1995). In 2003, Roshal et al. showed that inhibition of ATR (ataxia 
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telangiectasia mutated and Rad3-related protein), a sensor of replication stress, 
but not ATM (ataxia telangiectasia mutated) abrogates the ability of Vpr to induce 
G2 arrest (Roshal et al., 2003), suggesting that activation of ATR by Vpr was 
required for cell cycle arrest. 
Cellular replication stress is a downstream consequence of stalled 
replication forks, which can be induced by UV-light induced DNA damage, 
depletion of deoxyribonucleotide, and inhibition of topoisomerase (McGowan and 
Russell, 2004). ATR is a serine/threonine kinase that, upon activation by single 
stranded DNA, phosphorylates the replication protein A 32KDa subunit (RPA32), 
checkpoint kinase 1 (Chk1), histone 2A variant X (H2AX), p53-binding protein 
1(53AP1), and breast cancer-associated protein 1 (BRCA1) (Lai et al., 2005; Li et 
al., 2007; Roshal et al., 2003; Zimmerman et al., 2004), and induces formation of 
DNA-damage nuclear foci. Because Vpr does not induce DNA strand breaks to 
activate ATR, this observation leads to the hypothesis that Vpr is affecting an 
unknown upstream event that culminates in replication stress and ATR 
activation. 
In 1994, VprBP or RIP (Vpr-interacting protein) was first reported as a Vpr 
binding partner with unknown function (Zhao et al., 1994). It was only in 2006 
that several groups found VprBP as being associated with the DNA-damaged-
specific biding protein 1 (DDB1), a molecule that functions as an adaptor 
molecule for cullin-4 ubiquitin E3 ligase, and VprBP was renamed DCAF1 
(DDB1-cullin4 associated factor 1) (Angers et al., 2006; He et al., 2006; Higa et 
al., 2006; Jin et al., 2006). Rapidly, our group and others were able to show that 
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the ability of Vpr to induce G2 arrest is dependent on its interaction with DCAF1. 
siRNA depletion of DCAF1 inhibits G2/M arrest induced by Vpr by preventing Vpr 
from coimmunoprecipitating with DDB1, suggesting that DCAF1 is bridging Vpr 
onto Cul4 E3 ligase (DeHart et al., 2007; Hrecka et al., 2007; Wen et al., 2007). 
As a result of these observations, a model was developed suggesting that Vpr, 
through its interaction with DCAF1, binds to Cul4-DDB1 ubiquitin E3 ligase to 
trigger polyubiquitination and degradation of a specific cellular substrate (Figure 
1.2). When this substrate is degraded, ATR is activated, inducing G2 arrest. The 
3rd alpha helix of Vpr contains a leucine-rich motif that was characterized as the 
DCAF1 interaction domain (Figure 1.1). Mutations within this region, i.e., 
Vpr(Q65R), results in abrogation of DCAF1 interaction and failure to induce G2/M 
arrest (Le Rouzic et al., 2007; Zhao et al., 1994). Another mutant, Vpr(R80A), 
where the mutation is within the carboxy-terminal unstructured region of Vpr, is 
still able to bind to DCAF1 but does not arrest the cell cycle (DeHart et al., 2007; 
Le Rouzic et al., 2007). All together, these observations demonstrated that 
binding of Vpr to DCAF1 occurs within Vpr’s 3rd helix and it is required for 
induction of G2 arrest. Because the mutant Vpr(R80A) does not induce G2 arrest 
although binding to DCAF1 is preserved, it has been proposed that the carboxy-
terminal region of Vpr is the binding motif for the G2 arrest target protein (Dehart 






Vpr and Its Promiscuous Character 
Over the years, extensive searches have been undertaken in an attempt 
to identify the cellular protein that interacts with Vpr and could be implicated in 
Vpr’s induction of cell cycle arrest. Several groups were able to show, by distinct 
methods, that numerous host proteins interact with Vpr. Because of Vpr’s “sticky” 
characteristics, a great amount of Vpr’s binding partner seems to bind 
nonspecifically, while a few were characterized as true binding partners. The 
most studied binding partners of Vpr are described below. 
Using Y2H, the DNA repair enzyme uracil DNA glycosylase (UNG2) was 
identified as a Vpr binding protein (Bouhamdan et al., 1996). Insertion of uracil 
into DNA may occur through cytosine deamination or misincorporation of dUMP 
during DNA synthesis, resulting in mutagenesis. UNG2 prevents mutation by 
removing uracil from DNA.  In this process, the N-glycosylic bond is cleaved, 
generating an abasic site that is repaired by the base excision repair (BER) 
process (reviewed in Planelles and Benichou, 2009). It was observed that 
misincorporation of uracil into HIV-1 DNA occurs during reverse transcription 
(Kennedy et al., 2011) and generation of an abasic site by the enzyme UNG2 
could induce lethal mutations in the viral genome. 
  Although several groups described effects of UNG2 in HIV-1 biology, the 
function of UNG2 during HIV-1 infection remains extremely controversial. UNG2 
was described to be targeted by Vpr to the Cul4 E3 ubiquitin ligase, in a DCAF1-
dependent manner (Ahn et al., 2010; Schrofelbauer et al., 2007; Schrofelbauer et 
al., 2005), resulting in UNG2 ubiquitination and degradation. However, 
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degradation of UNG2 by Vpr is not associated with Vpr induction of G2 arrest 
(Selig et al., 1997). Interestingly, UNG2 was proposed to be a natural target of 
DCAF1 (Wen et al., 2012). Because Vpr was found to associate with hyper-
neddylated Cul4A, which represents a hyperactivated form of this E3 ligase 
(Hrecka et al., 2007), it is believed that degradation of UNG2 is accelerated in the 
presence of Vpr. This result explains the decreased level of UNG2 in the 
presence of Vpr and suggests that UNG2 degradation is a side effect of Vpr’s 
manipulation of the E3 ubiquitin ligase (Wen et al., 2012). 
In contrast to the destabilization effect of Vpr on UNG2, it was observed 
that UNG2 is encapsidated into the virion in a Vpr-dependent fashion (Selig et 
al., 1997). Vpr binds to UNG2 through the residue Trp54, which is found in the 
loop between the second and third alpha-helices. Incorporation of UNG2 into the 
virion influences the accuracy of the reverse transcriptase, ensuring the 
maintenance of the integrity of the viral genome (Chen et al., 2004). 
In 2014, Laguette et al. reported that the structure–specific endonuclease 
(SSE) regulator SLX4 complex (SLX4com) was targeted by Vpr to induce G2 
arrest. SLX4 was identified as a new Fanconi Anemia complex (FANCP or 
BTBD12) (Kim et al., 2013), which is involved in resolving Holiday junctions (HJ) 
during homologous recombination (HR) (Schwartz and Heyer, 2011). Fanconi 
Anemia is a disease characterized by a defect in DNA repair, which results in 
early onset of bone marrow failure and cancer. HR is a mechanism of high-
fidelity, template-dependent DNA repair that functions in the repair of double 
strand break (DSB) and interstrand crosslinks (ICLs), restoration of DNA gaps 
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and recovery of stalled replication forks, and is responsible for accurate 
chromosome segregation (reviewed in Li and Heyer, 2008). Inappropriate repair 
of the DNA damage and the inability to resolve DNA replication stress can result 
in genomic instability, which might lead to chromosome loss, apoptosis, and 
cancer (Hoeijmakers, 2001). During DNA DSB repair or restoration of stalled 
replication forks, an intermediate form of a four-way DNA junction (HJ) is created. 
In order to complete the DNA repair, the HJ must be resolved (reviewed in Kim et 
al., 2013). SLX4 has been implicated in resolution of HJ by recruiting SSEs, such 
as Mus81-Eme1 Ercc1-Errc4 and SLX1, to the sites of DNA lesions (reviewed in 
Kim et al., 2013). 
  Laguette et al. (2014) observed that DCAF1 interacts with SLX4com in the 
absence of Vpr and this interaction is enhanced when Vpr is present. 
Furthermore, the kinase PLK1 is recruited to the complex triggering EME1 
phosphorylation. Vpr-mediated remodeling of the SLX4com leads to Mus81 
ubiquitination and activation of the endonuclease complex. Because of the high 
error rate of the viral reverse transcriptase enzyme, an accumulation of 
nonproductive DNA is produced after HIV-1 infection, which can activate intrinsic 
cellular DNA sensors, resulting in an antiviral type-I IFN response. To overcome 
this effect, Vpr activates the SLX4com to process HIV-1 DNA, avoiding cellular 
immune recognition by DNA sensors, such as IFI16 (Jakobsen et al., 2013) and 
cGAs (Gao et al., 2013). As a side effect of aberrant activation of SLX4com, 
replication forks are processed abnormally, resulting in G2 arrest. SLX4com 
activation by Vpr was proposed to induce ATR activation, a hallmark of Vpr-
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induced cell cycle arrest. Conversely, in S. cerevisease, SLX4 activation was 
shown to occur downstream of ATR activation (Ohouo et al., 2010).  
It was observed that SLX4com interacts with Vpr in a DCAF1-dependent 
manner. WT Vpr but not Vpr(Q65R), the mutant that fails to bind to DCAF1, is 
still able to co-immunoprecipitate with SLX4 and Mus81. Interestingly, the mutant 
Vpr(R80A), which binds to DCAF1 but fails to induce G2 arrest, also interacts with 
SLX4 (Laguette et al., 2014). Recently, another group has observed that the 
ability of Vpr to induce cell cycle arrest was dependent on Vpr’s capacity to 
interact with SLX4 (Berger et al., 2014). Vpr was shown to induce modest 
degradation of Mus81 through manipulation of the Cul4DDB1/DCAF1 E3 ubiquitin 
ligase (Laguette et al., 2014). In agreement, we also found that Vpr induces 
degradation of Mus81 but in a DCAF1- and G2 arrest-independent manner, since 
Vpr(Q65R) and Vpr(R80A) were able to degrade Mus81 (see Chapter 2). 
Nevertheless, siRNA against Mus81 or any of the components of the SLX4com 
(SLX4, EME1, and SLX1) inhibits G2 arrest-induced by Vpr (Laguette et al., 
2014). This result diverges from the proposed model of G2 arrest, which 
implicates that Vpr induces ubiquitination and degradation of a cellular factor that 
culminates in cell cycle arrest (Andersen et al., 2008). To this end, down-
regulation of the Vpr target would mimic the G2 arrest induced by Vpr, the 
opposite result observed by Laguette et al. Furthermore, while all HIV/SIV 
accessory proteins that manipulate the UPS lead to degradation of a cellular 
protein, the effect observed by Laguette et al. is the opposite: upon 
ubiquitination, the complex is active instead of degraded. Because SLX4 binds to 
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DCAF1 constitutively, as an endogenous substrate, it seems that SLX4com 
activation by Vpr is a consequence of the hyperactivation of 
Cul4DDB1/DCAF1ubiquitin E3 ligase by Vpr. The same mechanism was suggested 
for UNG2 degradation in the presence of Vpr (Wen et al., 2012). 
 
Viral Manipulation of Host Ubiquitin E3 Ligase 
Viral infection and replication relies on the host cellular machinery. Due to 
the fact that the UPS controls protein functionality by posttranslational 
modification, it is not a surprise that viruses have evolved to co-opt the UPS to 
their own advantage. 
The UPS controls protein degradation, trafficking, signaling, cell cycle, and 
transcription by ubiquitination of targets. Ubiquitin is a small protein (76 amino 
acid) that is attached to target molecules to modify its function. Ubiquitination 
requires three sequential steps performed by three different enzymes: 1) 
ubiquitin activating enzyme (E1), through ATP-dependent reaction, activates the 
ubiquitin molecule by formation of a thiol ester bond between cysteine in the E1 
enzyme and the C-terminal glycine of ubiquitin; 2) activated ubiquitin is 
transferred, by trans-esterification, to a ubiquitin conjugating enzyme (E2); 3) The 
E2 then transfers the ubiquitin to the ε-amino group of a substrate lysine, 
resulting in an isopeptide bond (reviewed in  Randow and Lehner, 2009). The 
mammalian genome encodes two E1 enzymes, approximately 40 E2 enzymes, 
and more than 400 E3 ubiquitin ligases. There are three families of E3 ubiquitin 
ligases: RING (really interesting new gene) HECT (homologous to E6AP carboxy 
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terminus) and U-box-containing proteins like CHIP (carboxyl terminus of Hsc70-
interacting protein) (Ardley and Robinson, 2005; Deshaies and Joazeiro, 2009; 
Rotin and Kumar, 2009). The largest family of E3 ubiquitin ligases is the RING 
family and the complexes formed by cullin-RING are the most versatile class. 
Transfer of the ubiquitin to the substrate can occur in two different ways, 
depending on the type of E3 ubiquitin ligase. In the HECT type, the ubiquitin is 
transiently transferred first to the E3 ubiquitin ligase and then to the substrate; 
however, in the RING and U-box type, E3 ubiquitin ligase binds to the E2 and 
facilitates the transfer of the ubiquitin from the E2 conjugating enzyme directly to 
the substrate (reviewed in Randow and Lehner, 2009; van Wijk and Timmers, 
2010). While the E3 enzyme is responsible for the substrate specificity, the E2 
conjugating enzymes coordinate the ubiquitin linkage type, which dictates the 
fate of the target. The two most studied linkage types are Lys63 and Lys48 
chains. One example is the Lys63 chain induced by the E2 conjugating enzyme, 
ubc13. This type of linkage is involved in endocytosis, cellular trafficking, and 
DNA repair (Pan and Schmidt, 2014). The Lys48 linkage, in contrast, labels 
proteins for degradation by the proteasome system. 
Conjugation of ubiquitin to a target molecule is not permanent. 
Deubiquitinases (DUBs) and ubiquitin-like proteases function by removing the 
ubiquitin molecule from the targeted protein (Love et al., 2007). 
Viruses manipulate the E3 ubiquitin ligase to control cellular machinery 
and there are at least three different strategies adopted by viruses to change the 
E3 ligase substrate specificity: a) viral mimicry of endogenous substrate, such as 
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the mechanism used by HIV-1 Vpu to degrade CD4 by the Cul1-βTRCP 
(Margottin et al., 1998); b) displacement of the substrate specificity receptor of 
the E3 ubiquitin ligase, as seen in the case of degradation of APOBEC3G by Vif 
using Cul5-EloB/C (Yu et al., 2003); and c) the viral protein creates a new 
substrate interface within the ubiquitin E3 ligase, where the binding of the new 
target protein requires interaction with the viral protein and with the cellular 
substrate receptor. This last mechanism is employed by Vpx towards SAMHD1 
degradation by the Cul4DDB1/DCAF1 E3 ubiquitin ligase (Cassiday et al., 2014; 
Schwefel et al., 2014). 
Vpr and its paralog Vpx are approximately 50% identical in amino acid 
sequence and it is believed that Vpx was acquired by duplication of Vpr during 
the evolution of primate lentiviruses (Tristem et al., 1992). While Vpr is present in 
all primate lentiviruses, Vpx is only encoded by HIV-2, SIV of rhesus macaque 
(SIVmac), and SIV of sooty mangabeys (SIVsm). Despite the sequence similarity 
and the fact that both proteins utilize the same ubiquitin E3 ligase, they have very 
different functions. Vpx overcomes SAMHD1 restriction by inducing SAMHD1 
ubiquitination and degradation (Hrecka et al., 2011; Laguette et al., 2011). The 
N-terminal unstructured region of Vpx is required for this function (Ahn et al., 
2012; DeLucia et al., 2013). On the other hand, HIV-1 Vpr does not degrade 
SAMHD1 but induces G2 arrest through the Cul4DDB1/DCAF1 E3 ubiquitin ligase, a 
mechanism that requires HIV-1 Vpr C-terminal unstructured region (DeHart et al., 
2007; Di Marzio et al., 1995; Le Rouzic et al., 2007). Both Vpr and Vpx require a 
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leucine-rich domain, within their 3rd alpha helix, to interact with the cellular 
substrate receptor DCAF1 (Le Rouzic et al., 2007; Srivastava et al., 2008). 
The cellular substrate receptor DCAF1 is a large protein composed of 
several domains. The N-terminal domain is an armadillo domain, with unknown 
function. The LisH domain is found in the central part of DCAF1 and is proposed 
to be involved in dimerization of the molecule; the WD40 domain, which is 
common to all DCAFs, is also found in the central part of the molecule and it is 
involved in substrate interaction. The carboxy-terminal region comprises an 
acidic region that regulates DCAF1 activity (Nakagawa et al., 2013).  Because 
Vpr/Vpx interacts with the WD40 domain of DCAF, it was suggested that DCAF1 
functions as a bridge, linking Vpr/Vpx to the ubiquitin E3 ligase (Le Rouzic et al., 
2007; Schwefel et al., 2014). However, overexpression of a minimal domain of 
WD40 necessary to bind to DDB1 failed to induce G2 arrest by Vpr (Gerard et 
al., 2014), suggesting that DCAF1 is not simply functioning as a bridge. In 
agreement with that we found that overexpression of truncated domains of 
DCAF1 inhibit cell cycle arrest (unpublished data) and SAMHD1 degradation 
(Chapter 2).  
Recently, the solved crystal structure of a complex comprising the WD40 
domain of DCAF1, SIVsm Vpx, and the carboxy-terminal domain of smSAMHD1 
(Schwefel et al., 2014) demonstrated that the recruitment of SAMHD1 to the E3 
ubiquitin ligase occurs through direct interaction between SAMHD1, Vpx, and 
DCAF1, in a ternary complex. In agreement with this finding, we demonstrated 
that mutation at the residue D1092 of DCAF1, which was shown to mediate a 
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direct ionic interaction with the lysine 622 of SAMHD1 (Schwefel et al., 2014), 
although able to bind to Vpx is unable to interact with SAMHD1 (Chapter 2). This 
result suggests that a ternary complex between Vpx, DCAF1, and SAMHD1 must 
exist in order for Vpx degrade SAMHD1. 
 Using mutants of DCAF1, we observed that Vpr and Vpx, although sharing 
highly homology sequence and requiring the same conserved motif to interact 
with DCAF1, which is found in the 3rd alpha helix, use distinct residues in DCAF1 
for the interaction (Chapter 2)  
Its is known that the activity of culIins is controlled by neddylation (Saifee 
and Zheng, 2008). Neddylation is the covalent attachment of the ubiquitin-like 
molecule NEDD8 by specifics E2 conjugating enzymes (Ube2M and Ube2F) to 
cullins (Huang et al., 2009). Neddylation of cullins occurs on their C-terminal 
domain and induces a conformational change that shortens the distance between 
the substrate to the E3 ligase, facilitating the transfer of the ubiquitin molecule to 
the target protein (Saifee and Zheng, 2008). It was observed that Vpr associates 
with hyper neddylated Cul4A (Hrecka et al., 2007), suggesting that Vpr might 
enhance the interaction between the natural substrates with DCAF1 (Wen et al., 
2012), causing its premature ubiquitination (Hrecka et al., 2007). Recently, a new 
small molecule inhibitor called MLN4924 was shown to inhibit the NEDD8-
activating enzyme (NAE), blocking cullin neddylation, and inactivating Cullin Ring 
Ubiquitin Ligases (CRULs). MLN4924 was initially shown to block the capacity of 
HIV-1 Vif to degrade APOBEC3G (Stanley et al., 2012). Later, it was reported 
that MLN4924 also inhibited Vpx’s ability to degrade SAMHD1 (Hofmann et al., 
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2013; Wei et al., 2014). Our group found that this inhibitor also blocks the ability 
of Vpu to downregulate CD4, but it has no effect on BST2/Tetherin (see Chapter 
3). As expected, the NAE inhibitor impairs the induction of G2 arrest by Vpr 
(Ramirez et al. submitted for publication), confirming the requirement of the Cul4 













Figure 1.1 Three-dimension structure of the HIV-1 Vpr protein based on the NMR 
(Morellet et al., 2003). Vpr is comprised of three alpha helices (red) that are 
connected and flanked by flexible loops (green). The residue Trp54 is required to 
interact with UNG2. The third alpha helice (residues 55-77) contains the region 
necessary for interaction with DCAF1 (Q65). The carboxy-terminal unstructured 
region (C) is the predicted binding site for the G2 arrest putative target. 












Figure 1.2. Overview of the proposed mechanism used by HIV-1 Vpr to induce 
G2 arrest.  
Vpr interacts with the Cul4A-DDB1 E3 ligase via direct binding to DCAF1, leading 
to the recruitment of a host restriction factor for ubiquitination and degradation. 
Degradation of this putative protein activates ATR, which phosphorylates H2AX, 
BRCA1, p53, and Chk1. Chk1 phosphorylation phosphorylates CDC25c 
activating Cdk1 resulting in G2 arrest. Reproduced with permission from 
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Abstract 
Vpr and Vpx are a group of highly related accessory proteins from primate 
lentiviruses. Despite the high degree of amino acid homology within this group, 
these proteins can be highly divergent in their functions. In this work, we 
constructed chimeric and mutant proteins between HIV-1 and SIVagm Vpr in 
order to better understand the structure-function relationships. We tested these 
constructs for their abilities to induce G2 arrest in human cells and to degrade 
agmSAMHD1 and Mus81. We found that the C-terminus of HIV-1 Vpr, when 
transferred onto SIVagm Vpr, provides the latter with the de novo ability to induce 
G2 arrest in human cells. We confirmed that HIV-1 Vpr induces degradation of 
Mus81 although, surprisingly, degradation is independent and genetically 
separable from Vpr’s ability to induce G2 arrest. 
 
Introduction 
The HIV-1 genome encodes structural proteins (Gag, Pol, and Env), 
regulatory proteins (Tat and Rev), and accessory proteins such as Vif, Vpr, Vpu, 
and Nef. HIV-2, SIVmac, and SIVsmm encode Vpr, Vpx, Vif, and Nef as 
accessory proteins. Vpr and Vpx from HIV-2, SIVmac, and SIVsmm are highly 
related to each other and are thought to have arisen through gene duplication 
(Tristem et al., 1992). SIVagm encodes Vif, Vpr, and Nef. A Vpu homolog is not 
found in the HIV-2/SIVmac/SIVsmm or the SIVagm phylogenetic groups. 
From the entry step to the time of release from the host cell, lentiviruses 
encounter several restriction factors that function to inhibit viral infection and are 
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considered innate immune effector mechanisms. TRIM5α, APOBEC3G, sterile 
alpha motif (SAM) and HD domain-containing protein 1 (SAMHD1), and tetherin 
are examples of host restriction factors. These restriction factors are typically 
overcome by the accessory proteins encoded by lentiviruses (reviewed in 
Strebel, 2013).  
Three of the four accessory proteins in each HIV-1 (Vif, Vpr, and Vpu) and 
HIV-2 (Vif, Vpr, and Vpx) antagonize innate immunity by a common mechanism, 
the ubiquitin-proteasome system (UPS). These proteins modify the specificity of 
cullin-RING ubiquitin ligases (CRUL) such that noncognate proteins are modified 
and later degraded. 
Vpr has been associated with induction of cell cycle arrest in G2 and 
apoptosis (He et al., 1995; Jowett et al., 1995; Stewart et al., 1997). Vpr induces 
these effects via activation of the ATR kinase (Roshal et al., 2003), a result of 
manipulation of the ubiquitin ligase CRUL4DDB1/DCAF1 (Belzile et al., 2007; DeHart 
et al., 2007; Hrecka et al., 2007; Le Rouzic et al., 2007; Schrofelbauer et al., 
2007; Wen et al., 2007). Recently, the ubiquitination target for the Vpr/CRUL4 
complex has been identified (Laguette et al., 2014). Vpr induces premature 
activation of the SLX4 complex (SLX4com) (Laguette et al., 2014). Vpr increases 
the binding of DCAF1 to the scaffold protein SLX4 and, together with the polo-
like kinase-1 (PLK1), promotes SLX4com remodeling, which results in Mus81 
degradation (Laguette et al., 2014). As a consequence of the untimely SLX4com 
activation, replication forks are processed incorrectly, causing cell cycle arrest in 
G2 (Laguette et al., 2014). The authors showed that by activating SLX4, Vpr 
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prevents the viral DNA from stimulating cellular DNA sensors, which would 
normally trigger a type-I interferon response (Laguette et al., 2014)  
Nuclear magnetic resonance (NMR) studies indicate that HIV-1 Vpr is 
comprised of three bundled alpha helices connected by short flexible loops and 
flanked by flexible amino - and carboxy-terminal unstructured regions (Morellet et 
al., 2003). The region on Vpr that binds to DCAF1 was mapped within the third α-
helix, involving a leucine-rich motif (DeHart et al., 2007; Le Rouzic et al., 2007). 
The Vpr Q65R amino acid substitution within this region disrupts the interaction 
between Vpr and DCAF1, resulting in inability to induce G2 arrest (DeHart et al., 
2007; Le Rouzic et al., 2007). The C-terminal unstructured region of Vpr is 
predicted to be required for interaction with the target, since the mutant R80A 
within that region is capable of interacting with DCAF1 but is unable to cause G2 
arrest (DeHart et al., 2007). Furthermore, Vpr R80A acts as a dominant-negative 
protein because it binds to DCAF1 and blocks the Vpr-binding site (DeHart et al., 
2007; Le Rouzic et al., 2007). 
Vpx is encapsidated in HIV-2 and SIVmac virions and antagonizes 
SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011a). SAMHD1 interferes with 
the ability of the virus to efficiently synthesize viral cDNA during reverse 
transcription because it reduces the available cellular pools of dNTPs (Goldstone 
et al., 2011). Consequently, SAMHD1 diminishes the capacity of the virus to 
infect macrophages, dendritic cells, and quiescent T-cells wherein dNTP levels 
are normally very low (Hrecka et al., 2011; Laguette et al., 2011b). Vpx triggers 
degradation of SAMHD1 by associating with DCAF1 and recruiting SAMHD1 to 
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the CRUL4DDB1/DCAF1 E3 ligase. SAMHD1 is subsequently ubiquitinated and 
degraded by the proteasome. Inhibition of the interaction between Vpx and 
DCAF1 by the mutant Vpx(Q76A) results in failure to degrade SAMHD1. HIV-1 
Vpr and SIVmac Vpx appear to bind to similar or overlapping regions on DCAF1, 
although the amino acid residues in DCAF1 involved in interaction with either 
accessory protein are not identical (Cassiday et al., 2014).  
African green monkeys (AGM) are endemically infected with several 
strains of simian immunodeficiency viruses collectively known as SIVagm (Jin et 
al., 1994). This group of primate lentiviruses encode three accessory genes: Vpr, 
Vif, and Nef. SIVagm Vpr is bifunctional because it can induce G2 arrest and also 
antagonize SAMHD1. Unlike HIV-1 Vpr, SIVagm Vpr is highly species-specific, 
as it induces G2 arrest in AGM cells but not in human ones (Fletcher et al., 1996; 
Planelles et al., 1996), and is able to degrade agmSAMHD1 but not human 
SAMHD1 (hSAMHD1) (Lim et al., 2012).  
In order to understand the structure-function relationships for HIV-1 Vpr 
and SIVagm Vpr, we constructed chimeric proteins by exchanging homologous 
domains of HIV-1NL4-3 Vpr and SIVagm.gri Vpr. We then investigated the ability of 
the different chimeras to cause cell cycle arrest in G2 and to induce degradation 
of SAMHD1 and Mus81. We also investigated whether the structural 
requirements toward degradation of Mus81 are the same as those required for 
induction of G2 arrest by HIV-1 Vpr. 
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Results 
To study the structure-function relationships in HIV-1 Vpr and SIVagm 
Vpr, a set of 4 chimeras and 2 truncations were constructed, as shown in Figure 
2.1A. The exchange points for the chimeras were designed based on the 
published nuclear magnetic resonance (NMR) structure of HIV-1 Vpr and the 
high degree of amino acid homology with SIVagm Vpr (Figure 2.1B). 
 
Determinants Required for Induction of G2 Arrest 
 It was previously suggested that the C-terminal unstructured region of 
HIV-1 Vpr was required to interact with a putative G2 arrest-related cellular factor 
(DeHart et al., 2007; Di Marzio et al., 1995; Le Rouzic et al., 2007). In support of 
the previous notion, the point mutant Vpr(R80A), although capable of interacting 
with DCAF1, was unable to induce G2 arrest, and behaved as a dominant-
negative protein by competing with wild-type Vpr for DCAF1 binding (DeHart et 
al., 2007). 
We first constructed two truncations in HIV-1 Vpr (Vpr1-80 and Vpr1-84; 
Figure 2.1 A. encoded by lentiviral vectors (Verrier et al., 2011). HeLa cells were 
then transduced with VSV-G-pseudotyped lentivirus vectors (Supplemental 
Figure 2.1) encoding HIV-1 Vpr, HIV-1 Vpr(R80A), or each of the indicated 
truncations. As shown in Figure 2.2A and 2.2B, HIV-1 Vpr, but not HIV-1 
Vpr(R80A), HIV-1 Vpr(1-80), or HIV-1 Vpr(1-84) induced cell cycle arrest. The 
percentages of cells transduced with the corresponding lentivirus vectors are 
shown in Supplemental Figure 2.2A. 
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While HIV-1 Vpr is able to induce cell cycle arrest in human and non-
human primate cells, SIVagm Vpr arrests AGM, but not human cells (Planelles et 
al., 1996). We asked whether transposition of the C-terminal domain (HIV-1 Vpr 
residues 78-96) onto SIVagm Vpr (Ch1) would confer upon SIVagm Vpr a de 
novo ability to induce G2 arrest in human cells.  As shown in Figure 2.2C and 
2.2D, Ch1 was able to induce G2 arrest in human cells. Therefore, the inability of 
SIVagm Vpr to function in human cells can be overcome by a determinant within 
the C-terminal domain of HIV-1 Vpr. 
Using the inactive truncation HIV-1 Vpr(1-80) as the recipient, we asked 
whether grafting the C-terminus of SIVagm Vpr (Ch2) would enable induction of 
G2 arrest in human cells. HeLa cells transduced with the Ch2 also underwent cell 
cycle arrest (Figure 2.2C and 2.2D). The C-terminal domain of SIVagm Vpr is 
intrinsically capable of recruiting the target, leading to G2 arrest in human cells 
when in the context of HIV-1 Vpr. One possible explanation for the previous 
observation is that, while DCAF1 is highly conserved across primate lentiviruses 
(Berger et al., 2014), the target protein may be variable. In addition, these 
observations suggest that the interaction of Vpr with the target may be 
dependent, in part, on determinants that lie upstream of the C-terminal domain of 
Vpr.  
In contrast with the above findings, transposition of the N-terminal 
unstructured region of HIV-1 Vpr to SIVagm Vpr (Ch3) did not confer upon this 
chimera the ability to induce G2 arrest in human cells (Figure 2.2C and 2.2D). 
The reciprocal exchange (Ch4), which contained most of HIV-1 Vpr with the N-
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terminus of SIVagm Vpr, was still capable of inducing arrest in human cells 
(Figure 2.2C and 2.2D). The above results indicate that the N-terminal 
unstructured region of HIV-1 Vpr is not required to induce cell cycle arrest.  
In an effort to test whether the chimeras maintained the capacity to fold 
correctly, we verified their abilities to interact with DCAF1. HIV-1 Vpr, SIVagm 
Vpr, and chimeras Ch1 to Ch4 were able to Co-IP with DCAF1 (Figure 2.3, lanes 
1 and 4). In contrast, the mutant HIV-1 Vpr(Q65R), did not efficiently co-IP with 
DCAF1 (Figure 2.3)   
 
The Amino Terminal Domain of SIVagm Vpr Is Required  
for Degradation of AgmSAMHD1 
SIVagm Vpr is bi-functional in AGM cells, where it can arrest cells in G2 
and induce degradation of agmSAMHD1. However, SIVagm Vpr, when 
expressed in human cells, is unable to perform either function (Lim and al., 
2012). We wished to analyze which domain(s) in SIVagm Vpr may be important 
for targeting agmSAMHD1 for degradation. To that end, we tested the chimeras 
between SIVagm Vpr and HIV-1 Vpr. AgmSAMHD1 was degraded by SIVmac 
Vpx and SIVagm Vpr (Figure 2.4A, lanes 5 and 6, respectively) but not by HIV-1 
Vpr (Figure 2.4, lane 4) as previously reported (Hrecka et al., 2011). Addition of 
epoxomycin to cells transfected with SIVagm Vpr prevented the degradation of 
agmSAMHD1 (compare lanes 6 and 11), confirming the involvement of the UPS. 
To examine the potential role of the C-terminal domain of SIVagm Vpr in 
degradation of agmSAMHD1, we tested Ch1. As shown in Figure 2.4A, lane 7, 
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Ch1 remained capable of inducing degradation of agmSAMHD1. Therefore, the 
C-terminal domain of SIVagm Vpr is dispensable for the degradation of 
SAMHD1. The reciprocal chimera (Ch2) in which the C-terminus of SIVagm Vpr 
was transferred onto HIV-1 Vpr (lane 8) failed to degrade agmSAMHD1. These 
results suggest that the C-terminal unstructured region of SIVagm Vpr is not 
sufficient to confer upon HIV-1 Vpr the ability to degrade agmSAMHD1.  
The N-terminal domain of SIVmac Vpx was previously shown to be 
required to overcome SAMHD1 restriction in myeloid cells (Ahn et al., 2012; 
DeLucia et al., 2013). To confirm this notion, we tested Ch3. As shown in Figure 
2.4A, lane 9, Ch3 failed to induce degradation of agmSAMHD1. We interpret 
these data to mean that the loss of the native N-terminal domain of SIVagm Vpr 
in Ch3 ablated the ability to target agmSAMHD1 for degradation. Previous 
findings for the related protein, SIVmac Vpx, demonstrated that its amino-
terminal domain is required to induce hSAMHD1 degradation (Ahn et al., 2012; 
DeLucia et al., 2013). Therefore, we speculate, by analogy, that the amino-
terminal domain of SIVagm Vpr is also required for degradation of agmSAMHD1.  
The Ch4, which contains the N-terminus of SIVagm Vpr (residues 1-26) 
followed by HIV-1 Vpr (residues 17-96), also failed to trigger degradation of 
agmSAMHD1 (Figure 2.4A, lane 10). Therefore, we conclude that the N-terminal 
domain of SIVagm Vpr, although required (see above), is not sufficient for this 
function. Recently, a crystal structure of a complex of 
DCAF1/SIVsmVpx/smSAMHD1 demonstrated that residues between the 2nd and 
3rd alpha helices of SIVsm Vpx interact with smSAMHD1 (Schwefel et al., 2014) 
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Therefore, by analogy, it is possible that a second determinant required for 
degradation of agmSAMHD1 might lie in the homologous location of SIVagm 
Vpr. Schwefel et al. identified two residues in SIVsm Vpx, Met62, and Ser63, 
which establish a hydrophobic interaction and a hydrogen bond, respectively, 
with Lys622 and Phe621 in SAMHD1. SIVagm Vpr does not have significant 
conservation in this area and, specifically, equivalent residues to Met62 and 
Ser63 are not present in SIVagm Vpr. 
 
Degradation of Mus81 Is Independent of Vpr’s Ability to 
Induce G2 Arrest 
The SLX4 complex was recently proposed as a target for HIV-1 Vpr 
(Laguette et al., 2014). In the presence of HIV-1 Vpr, the Mus81 protein, a 
constituent of the SLX4 complex, is ubiquitinated, contributing to the activation of 
the complex and leading to G2 arrest (Laguette et al., 2014).  We observed that 
HIV-1 Vpr induces degradation of Mus81 as reported by Laguette et al. (Laguette 
et al., 2014), although to a modest degree (Figure 2.5A).  
We then asked whether the degradation of Mus81 correlated with the 
ability of known HIV-1 Vpr mutants and homologues to induce G2 arrest. We 
conducted these experiments in the presence or absence of the neddylation 
inhibitor that blocks CRULs, MLN4924 (Soucy et al., 2009), or the proteasome 
inhibitor, Epoxomicin (Meng et al., 1999). Surprisingly, HIV-1 Vpr(R80A) (Figure 
2.5B, compare lanes 3 and 11,) and HIV-1 Vpr(Q65R) (compare lane 3 and 15 
and Supplemental Figure 2.3), two mutants that are deficient in G2 arrest 
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induction, degraded Mus81 to a similar degree as did wild-type HIV-1 Vpr. 
Degradation of Mus81 for the above experiment was quantified by densitometry 
(Figure 2.5C). Vpr(Q65R) is deficient in binding to DCAF1 and, therefore, to 
degrade Mus81, it may utilize a different DCAF than that involved in induction of 
G2 arrest. Vpr(R80A) is thought to be unable to bind the putative G2 arrest-
related target, but is still able to induce degradation of Mus81 (Figure 2.5B lane 
11). Therefore, it appears that the molecular determinants of Mus81 degradation 
induced by Vpr are different from those required for induction of G2 arrest.  
We then asked whether V5-Mus81 was degraded in the presence of 
chimeras 1-4 and also in the presence of Vpx and SIVagm Vpr. As depicted in 
Figure 2.5D, SIVmac Vpx and SIVagm Vpr did not induce degradation of Mus81 
(lanes 5 and 6). Ch1, a construct that induces G2 arrest, did not target Mus81 for 
degradation (lane 7). Ch2, which also induced G2 arrest, was able to induce 
degradation of Mus81 (lane 8). Therefore, as we showed above with the Vpr 
point mutants Q65R and R80A, the ability to induce G2 arrest does not correlate 
with degradation of Mus81 when using our chimeric constructs. Furthermore, 
Ch2 is able to induce Mus81 degradation in the absence of HIV-1 Vpr’s 
unstructured C-terminal domain, pointing at another important difference 
between the requirements for G2 arrest and degradation of Mus81.  
Transpositon of the N-terminus of HIV-1 Vpr into SIVagm Vpr (Ch3) did 
not lead to Mus81 degradation (Figure 2.5D, lane 9). Ch4, which contains the N-
terminus of SIVagm Vpr (residues 1-26) followed by HIV-1 Vpr (residues 17-96), 
induced degradation of Mus81 (Figure 2.5D, lane 10). These results suggest that 
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the N-terminal unstructured region of HIV-1 Vpr is also not critical for Mus81 
degradation. 
Inhibition of the proteasome with Epoxomicin caused stabilization of 
Mus81 in the presence of HIV-1 Vpr or HIV-1 Vpr(R80A) (Figure 2.5B, compare 
lanes 4 to 7 and 11 to 12, respectively) or HIV-1 Vpr(Q65R) (Supplemental 
Figure 2.3). Because Epoxomicin targets the proteasome, degradation of 
ubiquitinated proteins is inhibited (Meng et al., 1999). Blockade of Cullin activity 
by the neddylation inhibitor MLN4924 (Soucy et al., 2009) also stabilized Mus81 
in the presence of HIV-1 Vpr, HIV-1 Vpr(R80A) (Figure 2.5B; compare lanes 4 to 
8 and 11 to 13, respectively), and HIV-1 Vpr(Q65R) (Supplemental Figure 2.3). 
Interestingly, treatment with Epoxomicin, but not with MLN4924, led to the 
stabilization of Mus81 (Figure 2.5B, compare lane 3 with 5 and 6). This result 
suggests that Mus81 is controlled naturally by the ubiquitin proteasome system 
but independently of a CRUL. The above data, taken together with the 
observation that Vpr(Q65R) is active at inducing degradation of Mus81, suggests 
that Vpr manipulates a CRUL not containing DCAF1, for targeting Mus81. We 
also observed that SIVagm Vpr, which causes G2 arrest in AGM cells, was 
unable to degrade agmMus81 (Supplemental Figure 2.4), supporting that also for 
SIVagm Vpr, degradation of Mus81 is independent of the induction of G2 arrest.  
 
Discussion 
The main conclusions from this study are as follows: (i) the C-terminal 
unstructured region of HIV-1 Vpr contains a determinant required for induction of 
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G2 arrest; transfer of the C-terminus of HIV-1 Vpr onto SIVagm Vpr is sufficient to 
confer upon this chimera a de novo ability to induce G2 arrest in human cells; (ii) 
the carboxy-terminal unstructured region of SIVagm Vpr is intrinsically capable of 
recruiting the G2 arrest-related target in human cells when transferred onto HIV-1 
Vpr, but not in its native configuration within SIVagm Vpr; (iii) the amino-terminal 
domain of SIVagm Vpr is required for agmSAMHD1 degradation, although it is 
not sufficient; (iv) targeting Mus81 for degradation and induction of G2 arrest are 
independent, separable functions of HIV-1 Vpr; and (v) degradation of Mus81 by 
HIV-1 Vpr is proteasome- and cullin-dependent, although it is likely that DCAF1 
is not involved in this activity. 
The amino-terminal domain of SIVagm.gri Vpr, like the homologous 
regions in HIV-2 and SIVmac (Ahn et al., 2012; DeLucia et al., 2013), was 
required for degradation of agmSAMHD1. The crystallographic data for SIVsm 
Vpx (Schwefel et al., 2014) showed that Glu residues 15 and 16 establish ionic 
interactions with Arg residues 609 and 617, respectively, in SAMHD1. While 
residues Glu 15 and 16 are conserved in HIV-2, SIVmac, SIVsm, and SIVrcm 
Vpx, SIVagm Vpr only contains one Glu residue in the corresponding region (Glu 
16). Therefore, it is tempting to speculate that Glu 16 from SIVagm Vpr may 
interact with either Arg 609 or 617 in SAMHD1. 
Our observations suggest that the inability of SIVagm Vpr to induce G2 
arrest in human cells is not intrinsic to this protein, because its C-terminal 
domain, when grafted onto HIV-1 Vpr, generates a chimera that is active. 
Because SIVagm Vpr is able to bind hDCAF1, the species-specificity of this 
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protein likely can be explained based on the different ability to interact with SLX4 
complex in the different species. Recently, it has been reported that interaction 
between HIV-1 Vpr or SIV Vpr and SLX4 correlates with induction of G2 arrest 
(Berger et al., 2014). Since Mus81 is targeted for ubiquitination by Vpr (Laguette 
et al., 2014), we decided to focus on this protein to investigate whether the 
requirements for induction of G2/M arrest and Mus81 degradation were the same. 
We found that HIV-1 Vpr induced degradation of Mus81 through the proteasome 
system, by manipulating CRUL, since addition of Epoxomicin or MLN4924 
relieved this effect.  Interestingly, HIV-1 Vpr(R80A) and HIV-1 Vpr(Q65R) 
degraded Mus81 in our hands. Therefore, our findings, at first sight, appear to be 
at odds with those of Berger et al., who reported that knockdown of SLX4 (of 
which Mus81 is an integral component) abolished the cell cycle arrest by the 
lentiviral proteins (Berger et al., 2014). One possible explanation that might 
reconcile our findings with those of Berger et al. (Berger et al., 2014) could be if 
the modest degradation of Mus81 that we and Laguette et al. (Laguette et al., 
2014) observe is simply not essential for induction of G2 arrest. It would still 
remain to be explained why Vpr(R80A) is competent for interaction with the SLX4 






	   44	  
Materials and Methods 
Cell Lines and Transfections 
HeLa cells and HEK293FT (Invitrogen) were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM; Invitrogen, Carlsbad, CA) supplemented with 10% of 
fetal bovine serum (FBS) and 2mM of L-glutamine (Invitrogen). HEK293FT cells 
were transfected by Calcium Phosphate method, as previously described (Zhu et 
al., 2001). HeLa cells were transfected using FuGENE HD (Promega) according 
to manufacturer’s instructions 
 
Plasmids 
HA-HIV-1Vpr, HA-SIVagm.gri Vpr (from Grivet monkeys), HA-SIVmac Vpx, 
and each of the chimeras were PCR amplified and cloned into pFIN-EF1-GFP-
2A-mCherry-HA-WPRE, a kind gift of Dr. Susan Semple-Rowland (Verrier et al., 
2011) in place of mCherry-HA. The truncations HIV-1 Vpr(1-80) and HIV-1 Vpr(1-
84) were generated on HIV-1Vpr using QuickChange Lightning (Agilent 
Technologies). Mammalian expressing vector encoding HA-agmSAMHD1 was a 
kindly provided by Dr. Michael Emerman. Mus81 cDNA was purchased from 
DNASU, PCR amplified, N-terminus tagged with V5 epitope cloned into pFIN 
vector (without mCherry) in place of GFP.  
 
Immunoprecipitation and Western Blot 
Cells were washed in PBS and lysed in NETN buffer, in the presence of 
phosphatase (PhosSTOP; Roche) and protease (Complete EDTA free tablets; 
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Roche, Indianapolis, IN) inhibitors. The concentration of proteins were 
determined by PierceTM BCA (Thermo Scientific, Rockford, IL). Magnetic Beads 
(SIGMA-ALDRICH, St Louis, MO) were coated with anti-HA antibody (HA1.1, 
Covance) for 30 minutes at room temperature (RT). For immunoprecipitation, cell 
lysates were incubated with the beads coated with anti-HA for 1h at 4°C. Beads 
were washed 3 times with NETN buffer and proteins were eluted in Lamelli buffer 
and boiled for 10 minutes. Samples were subjected to SDS-PAGE on 4-12% 
acrylamide gel CriteronTM TGX gel (Bio-Rad, Hercules, CA) and transferred to 
PVDF membrane (EMD Millipore, Billerica, MA). For degradation assay, cells 
were lysed using SET buffer (1% SDS, 50mM tris-HCl, pH 7.4, 1mM EDTA) and 
boiled for 20 minutes. Samples were resolved by SDS-PAGE as described 
above. V5 antibody (Sigma Aldrich), β-actin (Sigma Aldrich), and rabbit 
polyclonal DCAF1 antibody were kindly provided by Dr. Ling-Jun Zhao (Saint 
Louis University). 
 
Cell Cycle Analysis 
HeLa cells were treated with trypsin, washed with PBS, and stained with 
Propidium Iodide (PI) using Hypotonic PI buffer (Sodium Citrate, Triton X-100, 
Propidium Iodide, RNAse). Samples were analyzed by flow cytometry for DNA 
content. FlowJo was then used to analyze the cell cycle. 
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Lentiviral Vectors 
Lentiviral vectors were produced in HEK293FT cells. Briefly, transfer 
plasmid (12.5µg), packaging plasmid (12.5µg), and envelope (5µg) plasmid were 
co-transfected in HEK293FT cells by calcium phosphate. Supernatants were 
collected every 12h until the monolayer died. Lentiviruses were concentrated by 
ultracentrifugation at 25,000rpm for 2h at 4°C. Viruses were titrated in HeLa cells.  
 
Drugs 
Epoxomicin (Calbiochem) was solubilized in DMSO and used at 1µM. 
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Figure 2.1. Construction of chimeras between HIV-1 Vpr and SIVagm Vpr.                           
A. Schematic representation of the chimeras between HIV-1 Vpr and SIVagm 
Vpr. HIV-1 Vpr is comprised of three alpha helices, symbolized as barrels, 
flanked by amino-and carboxy-terminal unstructured regions that are connected 
by short flexible loops. R represents HIV-1Vpr and AGM represents SIVagm.gri 
Vpr. The subscript numbers denote the amino acid residues. B. Alignment 
between HIV-1Vpr and SIVagm.gri Vpr, illustrating the amino acid conservation 
between these two strains. An asterisk indicates fully conserved residues; colon 
represents amino acid conservation with strongly similar properties; period 
designates amino acid conservation with weakly similar properties. Highlighted 
residues mark alpha helices and yellow stars mark residues Q65 and R80. 
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Figure 2.2. G2 arrest determinants are found in the C-terminal domains of HIV-1 
Vpr and SIVagm Vpr.               
A Cell cycle analysis of HeLa cells transduced with VSV-G-pseudotyped lentiviral 
vectors for HIV-1 Vpr, HIV-1 Vpr(R80A), HIV-1 Vpr(1-80), or HIV-1 Vpr(1-84). 
48h post transduction, DNA staining (propidium iodide) was used to quantify the 
cell cycle by flow cytometry. B. Positive values are above the mean percent of 
cells in G2 from 3 negative control repeats plus 3 times the standard deviation 
(line marked with an asterisk) corresponding to a 99.7% interval of confidence. C. 
Cell cycle analysis of HeLa cells transduced with VSV-G-pseudotyped lentiviral 
vectors for HIV-1 Vpr, SIVagm Vpr, and each of the chimeras. These 
experiments were performed at least three time. 
                                                                                                                               
 





Figure 2.3. Chimeras Co-IP with endogenous DCAF1.        
HEK293FT cells were transfected with HIV-1 Vpr, HIV-1 Vpr(Q65R), SIVagm.gri 
Vpr, or each of the chimeras. 48h post-transfection cells were lysed and 

















Figure 2.4. The N-Terminal unstructured domain of SIVagm Vpr is required for 
agmSAMHD1 degradation. 
293FT cells were co-transfected with HA-agmSAMHD1 and with vectors 
encoding HA-HIV-1 Vpr, HA-SIVagm Vpr, HA-SIVmac Vpx, or each of the 
chimeras. 48h post-transfection cells were harvested and the level of ectopic 
agmSAMHD1 was analyzed by Western blot using anti-HA. Results are 
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Figure 2.5. Degradation of Mus81 by HIV-1 Vpr is independent of its ability to 
induce G2 arrest.                  
A. HEK293FT cells were cotransfected with HA-HIV-1 Vpr (from 1µg to 0.05 µg) 
and constant amount of V5-Mus81. 48h after transfection, cells were lysed and 
the level of Mus81 was analyzed by Western blot using anti-V5 antibody. B. 
HEK293FT cells were cotransfected with V5-Mus81 and HIV-1Vpr, or HIV-1 
Vpr(R80A), or HIV-1 Vpr(Q65R). 18h prior to cell harvesting, Epoxomicin or 
MLN4924 were added to cells. Levels of exogenous Mus81 were measured by 
Western blot using anti-V5 antibody. C. Quantification of Mus81 normalized to β-
actin from panel B. The line indicates the basal level of Mus81 in the presence of 
empty vector. Protein level below this line represents degradation of Mus81. D. 
HEK293FT cells were cotransfected with V5-Mus81 and HIV-1 Vpr or SIVagm 
Vpr or SIVmac Vpx or each of the chimeras. E. Quantification of Mus81 
normalized to β-actin from panel D. 
 
 









S2.1. Schematic representation of the pFIN-EF1-GFP-2A-HA-Vpr-WPRE vector.                                                                                                                                        
The EF1 promoter drives the expression of GFP and HA-Vpr as a single 
polyprotein. Co-translational cleavage within the 2A site (between amino acid 
residues 18 and 19) results in equimolar amounts of both proteins. LTR (Long 
Term Repeat); EF-1 elongation factor 1 alpha promoter; GFP, green fluorescent 
protein; 2A-like cleavage peptide from porcine Teschovirus; WPRE (woodchuck 
hepatitis virus posttranscriptional regulatory element). Bacterial sequences for 















S2.2. Transduction efficiency of HeLa cells.            
The efficiency transduction was measured by GFP expression from the lentiviral 
vector. Further cell cycle experiments were only performed when the efficiency of 
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S2.3. HIV-1 Vpr(Q65R) degrades Mus81 in a proteasome and Cullin–dependent 
manner.                 
A. 293FT cells were transfected with human V5-Mus81 in the presence of HIV-1 
Vpr(WT) or HIV-1 Vpr(Q65R). 48h post-transfection cells were harvested and the 
level of Mus81 was analyzed using anti-V5 antibody. B. Bar graph representation 
of the level of hMus81. The amount of Mus81 was normalized to the β-actin. 











S2.4. agmMus81 is not degraded by SIVagm Vpr. 
A.293FT cells were transfected with human V5-Mus81 (hMUS81) or V5-
agmMus81 in the presence of HIV-1 Vpr or SIVagm Vpr. 48h post-transfection 
cells were harvested and the level of Mus81 was analyzed using anti-V5 
antibody. B) Bar graph representation of the level of hMus81 (dark grey) and 
agmMus81 (light grey) for the experiment above. The amount of Mus81 was 
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a b s t r a c t
Vpr and Vpx are primate lentivirus proteins that manipulate the cellular CRL4 ubiquitin ligase complex.
While Vpr is common to all primate lentiviruses, Vpx is only encoded by HIV-2 and a limited range of
SIVs. Although Vpr and Vpx share a high degree of homology they are known to induce markedly
different effects in host cell biology through the recruitment of different substrates to CRL4. Here we
explore the interaction of HIV-1 Vpr and SIVmac Vpx with the CRL4 substrate receptor DCAF1. Through
mutational analysis of DCAF1 we demonstrate that although Vpr and Vpx share a highly similar DCAF1-
binding motif, they interact with a different set of residues in DCAF1. In addition, we show that Vpx
recruits SAMHD1 through a protein–protein interface that includes interactions of SAMHD1 with both
Vpx and DCAF1, as was ﬁrst suggested in crystallography data by (Schwefel, D., Groom, H.C.T., Boucherit,
V.C., Christodoulou, E., Walker, P.A., Stoye, J.P., Bishop, K.N., Taylor, I.A., 2014. Structural basis of lentiviral
subversion of a cellular protein degradation pathway., Nature, 505, 234–238).
& 2014 Elsevier Inc. All rights reserved.
Introduction
Many viruses encode proteins that manipulate the cellular
ubiquitin proteasome system (UPS) to degrade cellular restriction
factors. Human Immunodeﬁciency Virus type-1 (HIV-1) encodes
three such proteins (Vif, Vpu, and Vpr). In addition, some primate
lentiviruses (including HIV-2 and SIVmac) encode the Vpr paralog,
Vpx. While the mechanism of UPS manipulation and the cellular
targets of Vif and Vpu have been well characterized, the functions
of Vpr and Vpx have been more difﬁcult to elucidate (reviewed in
Guenzel et al. (2014), Malim and Emerman (2008) and Romani and
Cohen (2012)). In 2011, two groups independently identiﬁed
SAMHD1 as the cellular protein targeted by Vpx (Hrecka et al.,
2011; Laguette et al., 2011). More recently, Laguette et al. (2014)
proposed that Vpr activates the SLX4 complex in a ubiquitin
dependent manner.
Vpr is a short, 96-amino acid protein that is highly conserved
among primate lentiviruses, which is expressed late during viral
replication and is present in virions (Cohen et al., 1990; Müller
et al., 2000). Vpr and its function appear to be crucial for HIV
infection as no primary isolates have been described which lack
Vpr (reviewed in Andersen et al. (2008)). While Vpr induces cell-
cycle arrest at the G2/M transition through the activation of the
DNA damage sensor Ataxia Telangiectasia and Rad3-related pro-
tein (ATR) (Roshal et al., 2003), the signiﬁcance of this cell cycle
arrest in the virus life cycle remains unclear (reviewed in
Andersen et al. (2008)). Recently, it was proposed that G2 arrest
is initiated by the Vpr-mediated activation of the SLX4, presum-
ably generating aberrant damage to the host genome and activa-
tion of the cellular DNA damage response (Laguette et al., 2014).
In 1994, Vpr was shown to interact with a novel cellular protein
(Zhao et al., 1994), subsequently named DDB1-Cullin 4-Associated
Factor 1 (DCAF1). The signiﬁcance of this interaction remained
uncertain until DCAF1 was identiﬁed as a substrate receptor for
the Cullin 4-RING E3 ligase (CRL4) (Angers et al., 2006; He et al.,
2006; Higa et al., 2006; Jin et al., 2006). Subsequent studies
demonstrated that induction of G2 arrest by Vpr was dependent
on the manipulation of CRL4DCAF1 (Belzile et al., 2007; Dehart et al.,
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2007; Hrecka et al., 2007; Le Rouzic et al., 2007; Schröfelbauer
et al., 2007; Tan et al., 2007; Wen et al., 2007).
In addition to Vpr, some primate lentiviral lineages encode the
Vpr paralog, Vpx. Early studies identiﬁed a role for Vpx in the
infection of myeloid lineage cells, dendritic cells and macrophages,
by overcoming a block to viral reverse transcription (Yu et al.,
1991; Goujon et al., 2008). Similar to Vpr, the Skowronski and
Stevenson laboratories demonstrated that this Vpx-mediated
effect requires the formation of a Vpx-CRL4DCAF1 complex
(Sharova et al., 2008; Srivastava et al., 2008). In 2011, SAMHD1
was identiﬁed as the cellular protein targeted by Vpx, in the
context of CRL4DCAF1 (Hrecka et al., 2011; Laguette et al., 2011).
Thus far, three mechanisms for viral directed ubiquitination of
cellular proteins have been observed: 1) the encoding of a viral E3
ubiquitin ligase, as is the case of the ICP0 protein of Herpes
Simplex 1 (Boutell et al., 2002; Everett, 2000); 2) the replacement
of the substrate receptor of a cellular ubiquitin ligase by a virally
encoded protein, as is the case of protein V from SV5 (Horvath,
2004) and Vif from primate lentiviruses (Mehle et al., 2004;
Sheehy et al., 2003; Yu et al., 2003); and 3) mimicry of an
endogenous substrate by the viral protein, which then ferries a
cellular protein to be targeted for ubiquitination, as observed in
the manipulation of CRL1βTRCP by HIV-1 Vpu to target CD4 (Bour
et al., 2001; Margottin et al., 1998).
In this study we investigated the manner in which HIV-1 Vpr
and SIVmac Vpx (hereafter referred to as “Vpr” and “Vpx”,
respectively) interact with DCAF1 resulting in the alteration of
substrate speciﬁcity of CRL4DCAF1. Using mutational analysis of the
DCAF1 substrate-binding interface we found that although Vpr
and Vpx share a highly homologous DCAF1-binding motif on their
third alpha helix, Vpr and Vpx interact with CRL4DCAF1 using
different residues on DCAF1. In addition, we identiﬁed the DCAF1
residues, D1092 which, when mutated, disrupted SAMHD1 degra-
dation without impeding Vpx binding. Therefore, we surmise that
the recruitment of SAMHD1 to DCAF1 by Vpx is mediated by a
combination of residues in Vpx and DCAF1. Our results conﬁrm
and expand on a functional level the intermolecular interactions
that were previously identiﬁed by Schwefel et al. (2014) via a co-
crystal that included the DCAF1 WD40 domain, the C-terminal
domain of SAMHD1 and Vpx.
Materials and methods
Cell culture
Exponentially growing 293FT cells were cultured in Dulbecco
minimal essential medium (DMEM; Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (FBS) and 1% L-glutamine
(Invitrogen). 293FT cells were transfected using the Calcium Phos-
phate method, as previously described (Zhu et al., 2001). Cells were
harvested 36 h post-transfection, washed 2x with Phosphate Buf-
fered Saline (PBS) and lysed as described below.
Plasmids
DCAF1 Iso1 cDNA (NCBI accession NM_014703) was ampliﬁed by
PCR from a human cDNA library with the addition of an N-terminal
3x FLAGs-poly linker, then assembled into pCMV.Sport 6 (Invitro-
gen, Carlsbad, CA). DCAF1 truncations were made by generating
unique restrictions sites which were indicated (Fig. 1A) using
Quikchange Lightning site-directed mutagenesis (Agilent Technol-
ogies, Santa Clara, CA). DCAF1 WD40 point mutants were also
generated via Quikchange. Myc-huSAMHD1 was purchased from
OriGene (Rockville, MD). pcDNA3.1 was purchased from Invitrogen.
HA-Vpr of HIV-1 and HA-Vpx of SIVmac were subcloned from
pHR-HA-Vpr-IRES-GFP and pHR-HA-Vpx-IRES-GFP, respectively
(Dehart et al., 2007) into pFIN-EF1-GFP-2a-mCherH-WPRE (a kind
gift of Dr. Semple-Rowland) (Verrier et al., 2011) in substitution of
the mCherry gene.
Immunoprecipitation and Western blots
For immunoprecipitation, cells were gently detached by incubation
in PBS, pelleted and lysed with FLAG IP buffer (50 mM Tris HCI, pH 7.4,
15 0 mM NaCl, 1 mM EDTA and 1% TRITON X-100) in the presence of
protease inhibitors (Complete EDTA free tablets; Roche, Indianapolis,
IN). Lysate protein concentrations were determined by Pierce™ BCA
(Thermo Scientiﬁc, Rockford, IL) and brought to equal protein con-
centration. Lysates were subjected to immunoprecipitation using Anti-
FLAGs M2 Magnetic Beads (SIGMA-ALDRICH, St. Louis, MO). Brieﬂy,
lysates were incubated with beads for 2 h (at RT) to overnight (at 4 1C).
Beads were washed 5x with lysis buffer and proteins eluted with 3x-
FLAGs Peptide, 100 mg/ml, for 1 h at RT. Cells used in degradation
assays were lysed in SET Buffer (1% SDS, 50 mM Tris HCL, pH 7.4, 1 mM
EDTA); lysates were thoroughly denatured by boiling for 5 min.
Lysates and immunoprecipitation samples were resolved by SDS-
PAGE on 4–10% Criteron™ TGX™ gels (Bio Rad, Hercules, CA) as per
manufacturer's recommendations and transferred to PVDF membrane
(EMD Millipore, Billerica, MA). The following antibodies were used:
Fig. 1. The WD40 domain of DCAF1 is necessary for interaction with DDB1. (A) Domain
architecture of WT DCAF1 (Isoform 1) and truncations. (B) 293FT cells were transfected
with plasmids expressing FLAG-DCAF1 or the truncations described in (A). 36 h post-
transfection cell lysates were subject to FLAG-immunoprecipitation (DCAF1) and
analyzed for the presence of DDB1 by Western blot.
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FLAGsM2 and β-actin (Sigma-Aldrich), HA.11 and 9E11(c-Myc)(Cov-
ance), and DDB1 and VprBP/DCAF1 (Abcam).
DCAF1 depletion
DCAF1 was knockdown using an shRNA expression plasmid
previously described (Ward et al., 2009). Brieﬂy, 293FT cells were
transfected as described above with FG12 DCAF1_3590 and FG12
DCAF1_Scambled vectors graciously provided by Dr. Edward
Barker (Rush University Medical Center, Chicago, Illinois).
DCAF1_3590 target and scrambled sequences were previously
described (Hrecka et al., 2007; Ward et al., 2009). Transfected
cells were analyzed for DCAF1 depletions 48 h later by Western
blot using rabbit anti-DCAF1 (Abcam).
Results and discussion
DCAF1 interacts with DDB1 through a region N-terminal of the WD40
domain
Most DCAFs consist primarily of a WD40 domain (Higa et al.,
2006), a highly conserved β-propeller structure involved in med-
iating protein–protein interactions (Stirnimann et al., 2010). In
contrast, DCAF1 has a complex domain architecture, comprised of
an N-terminal armadillo domain (“Arm”), a central LisH domain, a
WD40 domain and a highly acidic C-terminal tail (Jin et al., 2006)
(Fig. 1A, isoform 1). Several groups have previously shown that Vpr
and Vpx interact with the DCAF1 WD40 domain (Gérard et al.,
2014; Le Rouzic et al., 2007; Schwefel et al., 2014). Whether the
other domains are required for viral proteins to alter substrate
speciﬁcity remains unknown. In order to better understand how
Vpx manipulates the CRL4DCAF1 ubiquitin ligase, we generated a
number of FLAG-tagged DCAF1 constructs in which each domain
was removed individually or in conjunction with others. We also
generated a construct reﬂecting the structure of the annotated
DCAF1 isoform 3 (Uniprot identiﬁer Q9Y4B6-3), which is char-
acterized by a large truncation within the Arm domain (Fig. 1A).
DCAF1-mediated substrate ubiquitination is dependent on the
interaction of DCAF1 with the ubiquitin ligase backbone com-
prised of DDB1-Cullin 4-Roc1 (Angers et al., 2006; Hu et al., 2004).
To determine the minimal DCAF1 construct capable of interacting
with DDB1, we performed immunoprecipitation studies. 293FT
cells were transfected with expression vectors encoding the
indicated DCAF1 truncations, subjected to FLAG immunoprecipita-
tion and analyzed for the presence of DDB1. As expected, full
length DCAF1, both isoform 1 (“WT”) and isoform 3, were capable
of interacting with DDB1 (Fig. 1B, lanes 2 and 3). Consistent with
previous observations indicating a role of the WD40 domain in
DDB1 interaction (Angers et al., 2006), constructs lacking the
WD40 domain lost the ability to interact with DDB1 (Fig. 1B, lanes
4, 6–8). Surprisingly, the FLAG-DCAF1 WD40 construct did not
interact with DDB1 (Fig. 1B, lane 11). This is in contrast to earlier
reports in which the WD40 domain by itself was shown to be able
to interact with DDB1 (Gérard et al., 2014; Le Rouzic et al., 2007).
Most likely this discrepancy is due to differences in residues
spanned by the constructs used in these different studies (residues
1041–1377 (Le Rouzic et al., 2007); 1041–1393 (Gérard et al.,
2014); and 1073–1396 in this study). Interaction between DCAFs
and DDB1 is facilitated by a cryptic α-helix located N-terminal to
the WD40 domain, termed an Hbox (Li et al., 2009). Gérard et al.
(2014) recently determined that the putative DCAF1 Hbox spans
residues 1049–1062, a stretch of residues which is absent from our
WD40 construct. In agreement with this hypothesis the minimal
truncation we generated of DCAF1 was capable of interacting with
DDB1 containing the LisH and WD40 domains (Fig. 1B, lane 9). The
∆-acidic DCAF1 construct was unable to interact with DDB1
(Fig. 1B, lane 5). This was a surprising result in view of the
observation that the construct containing LisH-WD40 domains
was sufﬁcient to bind to DDB1. The simplest explanation for these
observations would be that ∆-acidic DCAF1 construct is incorrectly
folded and lost the ability to bind to DDB1 even though all the
necessary domains may be present.
Mutations in the predicted DCAF1 WD40 substrate interface disrupt
Vpx-mediated SAMHD1 degradation
We then tested the DCAF1 LisH-WD40 and WD40 constructs
for their ability to facilitate SAMHD1 degradation by Vpx. To
determine the residues necessary for SIVmac Vpx to manipulate
the substrate speciﬁcity of DCAF1, we also generated a number of
point mutations in the WD40 domain of DCAF1 (Table 1). Sub-
strate binding to WD40 domains is typically mediated by polar
interactions on the “top” side (by convention) of the β-propeller
structure (Patel et al., 2008; Pons et al., 2008). Previous reports
have demonstrated that the top of WD40 domains form a shallow
groove that mediates interactions with proteins to be targeted for
ubiquitination (reviewed in Stirnimann et al. (2010) and Trievel
and Shilatifard (2009)). We utilized two independent methods to
Table 1
Summary of DCAF1 mutants. DCAF1 mutations were screened for their ability to
facilate Vpx-mediated SAMHD1 degradation or interact with DDB1, Vpx and Vpr as
indicated. “þ” indicates that SAMHD1 degradation was observed in the presence of
the DCAF1 construct or the DCAF1 construct was able to interact with indicated
protein. “"” denotes that SAMHD1 degradation was not observed in the presences
of the DCAF1 construct or the DCAF1 construct was unable to co-IP the indicated
protein. The two constructs for which SAMHD1 degradation was observed to be
intermediated are denoted with “þ/"”. ND indicates that the DCAF1 construct was
not tested for the indicated activity.
Function Interaction
SAMHD1 Deg Vpx Vpr DDB1
Iso1 þ þ þ þ
Iso3 ND ND ND þ
∆WD40 ND ND ND "
∆Acid ND ND ND "
∆WD40-∆Acid ND ND ND "
Arm-Iso1 ND ND ND "
Arm-Iso3 ND ND ND "
Lish-WD40 " þ þ þ
∆Arm ND ND ND þ
WD40 " " þ "
WD40-Acid ND ND ND "
Acid ND ND ND "
∆Lish ND ND ND "
D1092A " þ þ þ
H1134A þ þ þ þ
N1135A þ/" " þ þ
T1141A þ ND þ ND
T1155A þ ND þ ND
W1156H " " þ þ
E1178A-D1179A þ ND þ ND
H1180A þ ND þ ND
K1196A þ ND þ ND
N1221A-N1222A þ ND þ ND
R1225A þ ND þ ND
N1226A þ ND þ ND
D1256A þ þ þ þ
K1257A þ ND þ ND
S1263A þ ND ND ND
D1295A þ ND ND ND
Q1296A þ ND þ ND
Q1316A þ ND þ ND
D1320A þ ND ND ND
F1334Y þ ND þ ND
V1350T þ ND þ ND
N1379A þ ND ND ND
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select a number of polar/charged residues, which we predicted
may be involved in binding to Vpx based on their predicted
location within the top face of DCAF1 WD40 domain: 1) homology
modeling between DCAF1 and the most closely related DCAF with
a known crystal structure (WDR5; Fig. 2A) (Patel et al., 2008;
Schuetz et al., 2006; Song and Kingston, 2008) by alignment of
primary sequences using ClustalW2 (Larkin et al., 2007) and 2) an
in silico (ModBase) structural prediction of the DCAF1 WD40
domain (Pieper et al., 2014). Selected residues were then mutated
to alanine. In addition, three hydrophobic residues (W1156, F1334
and V1350) were mutated, to polar amino acids of similar size,
based on their predicted proximity to and orientation towards the
Fig. 2. Analysis of DCAF1 mutations for their ability to facilitate Vpx-mediated SAMHD1 degradation. (A) DCAF1 WD40 domain and WDR5 protein sequences were aligned
and used to predict DCAF1 WD40 secondary structure. WDR5 tertiary structure is indicated below (bold lines – β-sheets, narrow lines connect β-sheets which form
respective “blades” of the β-propeller. Homology is indicated below: asterisks (n) indicate identity, colons (:) and periods (.), similarity. Arrowheads indicate residues mutated
in DCAF1. Residues observed to be important for Vpx mediated SAMHD1 degradation are indicted with a pound symbol (#) above the arrowhead. B) DCAF1 WD40 domain as
determined by Schwefel et al. (2014) (PDB accession 4CC9). The side chains for the three loss-of function mutants (D1092, N1135 and W1156) are shown in red, and those for
two control mutants (H1134 and D1256) are shown in cyan, additional residues screened are shown without side chains in purple. (C) 293FT cells were transfected with
human Myc-SAMHD1, HA-Vpx and/or FLAG-DCAF1 mutants. 36 h post-transfection, cells were lysed and analyzed for the presence of SAMHD1 by Western blot. (D) FLAG-
DCAF1 constructs were tested for the ability to facilitate Vpx-mediated degradation Myc-SAMHD1 in DCAF1 depleted 293FT cells. (E) Transfection of DCAF1 shRNA
expression construct efﬁciently depleted DCAF1 in 293FT cells.
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predicted substrate-binding groove. Finally, based on the recent
observations by Schwefel et al., we mutated residue D1092 in
order to functionally test its role in SAMHD1 recruitment by Vpx
(Schwefel et al., 2014). Mutated residues are represented as
arrowheads in Fig. 2A and colored (other than green) residues in
Fig. 2C.
293FT cells were transfected with DCAF1 expression constructs,
SAMHD1 and Vpx as indicated. Because endogenous DCAF1 was
not depleted in this experiment, this method evaluated the
abilities of indicated constructs to dominantly inhibit degradation
of SAMHD1. 36 h post-transfection cells were lysed and SAMHD1
degradation was analyzed by Western blot. As LisH-WD40 or
WD40 (Fig. 2C, lanes 8 and 9) constructs were unable to mediate
SAMHD1 degradation we propose that DCAF1 does not merely
serve as a bridge by which Vpx brings SAMHD1 to the CRL4DCAF1
ubiquitin ligase. Rather, additional domains of DCAF1 appear to be
necessary to facilitate this activity.
Two DCAF1 point mutants (D1092A, and W1156H) were
identiﬁed which failed to mediate the degradation of SAMHD1 in
the presence of Vpx while a third point mutant (N1135A) showed
reduced ability to facilitate SAMHD1 degradation by Vpx (Fig. 2C,
lanes 10, 12–13). Other point mutants (H1134A and D1256A) in the
DCAF1 WD40 domain (Fig. 2C, lanes 11 and 14), as well as all
additional point mutations in the DCAF1 WD40 domain (Table 1)
retained the ability to support Vpx-induced degradation of
SAMHD1. For simplicity, data corresponding to the three loss-of-
function mutants (side chains shown in red in Fig. 2B), as well as
two control mutants (side chains shown in cyan in Fig. 2B), are
shown and the overall results for all mutants are summarized in
Table 1.
In order to conﬁrm these results in the absence of potential
contribution of endogenous DCAF1 to the degradation of SAMHD1,
293FT cells were co-transfected with a DCAF1 shRNA expressing
plasmid, Myc-SAMHD1, FLAG-DCAF1 constructs and HA-Vpx as
indicated. FLAG-DCAF1 constructs were protected from shRNA
depletion by the generation of silent mutations at the shRNA-
targeting site. 48 h post-transfection, cells were lysed and ana-
lyzed for SAMHD1 degradation by Western blot (Fig. 2D–E). As
expected, Vpx was unable to facilitate the degradation of SAMHD1
in the absence of endogenous DCAF1 while the expression of WT
DCAF1 was able to restore Vpx mediated SAMHD1 degradation
(Fig. 2D lane 5 vs. 6). Conﬁrming the observations depicted in
Fig. 2C, DCAF1 W1156H was unable to elicit the degradation of
SAMHD1 and DCAF1 N1135A exhibited an intermediate phenotype
(Fig. 2D, lanes 9 and 8, respectively). The mutant DCAF1 H1134A
was able to recover Vpx mediated SAMHD1 degradation in DCAF1-
depleted cells (Fig. 2D lane 7). The efﬁciency of DCAF1 depletion
by shRNA is shown in Fig. 2E.
Select DCAF1 WD40 domain mutations disrupt Vpx binding
To better understand how the above DCAF1 truncations/sub-
stitutions (LisH-WD40, WD40, D1092A, H1134A, N1135A, W1156H
and D1256A) disrupt Vpx function, we analyzed the ability of each
to interact with Vpx by co-IP. As expected, immunoprecipitation of
full-length FLAG-DCAF1 was able to co-precipitate Vpx (Fig. 3, lane
4). Interestingly, in contrast to previous reports regarding the
highly related lentiviral protein HIV-1 Vpr (Le Rouzic et al. (2007)
and this report), the WD40 domain of DCAF1, alone, was not
sufﬁcient to co-IP with Vpx (Fig. 3, lane 5), while the longer
construct containing both LisH and WD40 domains retained this
function (Fig. 3, lane 6). These observations suggest that the Vpx–
DCAF1 interaction may involve residues outside the WD40 region
in addition to those within. Alternatively, it is also possible that the
presence of the LisH domain is required for the WD40 domain to
retain its native conformation.
While DCAF1 mutations D1092A, N1135A and W1156H all dis-
rupted Vpx-mediated SAMHD1 degradation, only N1135A and
W1156H (Fig. 3, lanes 9 and 10) resulted in a loss of Vpx interaction.
Residue D1092 in DCAF1 was recently shown to form a direct ionic
interaction with residue K622 of SAMHD1 (Schwefel et al., 2014). This
is consistent with our observation that DCAF1 D1092Awas still able to
bind to Vpx (Fig. 3, lane 7) but not to facilitate the degradation
SAMHD1. Therefore, our results functionally conﬁrm and extend the
ﬁndings by Schwefel et al. (2014) and suggest that the interaction of
Vpx with DCAF1 leads to the formation of a new protein–protein
interface that recruits SAMHD1 via interactions with both DCAF1 and
Vpx residues (Fig. 4). These observations taken together functional
conﬁrm the crystallographic data of Schwefel et al. demonstrating the
importance of residues N1135 and W1156 in binding the Vpx Q76
residue.
Vpr interacts with different residues in DCAF1 than those utilized
by Vpx
While a recently published crystallographic study identiﬁed the
Vpx–DCAF1 binding interface (Schwefel et al., 2014), no structural data
exists regarding the Vpr–DCAF1 interaction. The existence of a high
degree of homology between HIV-1 Vpr and SIVmac Vpx led us to
hypothesize that both viral proteins would interact with DCAF1 in a
similar manner. We speculated that the same set of residues in DCAF1
might mediate interactions with both viral proteins. In support of this
hypothesis, analogous mutations in the third helix of both Vpr (Q65R)
and Vpx (Q76R) have been shown to abrogate interaction with DCAF1
(Belzile et al., 2007; Dehart et al., 2007; Le Rouzic et al., 2007;
Schröfelbauer et al., 2007; Srivastava et al., 2008).
In order to examine the molecular interaction between DCAF1
and Vpr, we tested our panel of DCAF1 truncations and point
mutants for their ability to interact with Vpr. As a positive control,
wild-type Vpr was able to co-IP with FLAG-DCAF1 (Fig. 5A, lane 4).
In agreement with previous observations (Le Rouzic et al., 2007)
the DCAF1 WD40 domain alone was sufﬁcient to mediate Vpr
binding (Fig. 5A, lane 5). The longer LisH-WD40-containing con-
struct also retained Vpr binding (Fig. 5A, lane 6). In contrast to
what we observed with Vpx, both N1135A and W1156H DCAF1
substitutions retained Vpr binding (Fig. 5A, lanes 9 and 10).
Fig. 3. DCAF1 mutations differentially effect interaction with Vpx. 293FT cells were
transfected with plasmids expressing FLAG-DCAF1 or mutants and HA-Vpx as
indicated. Cell lysates were subject to FLAG-immunoprecipitation and analyzed for
the presence of HA-Vpx by Western blot.
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Therefore residues N1135 and W1156 are required for interaction
of DCAF1 with Vpx but not with Vpr. We conclude that Vpr and
Vpx interact with a non-identical set of residues in DCAF1 WD40
domain.
A previous study by Gérard et al. (2014) explored the interac-
tion between DCAF1 and HIV-1 Vpr by investigating the potential
role of F/YxxF/Y motifs within the DCAF1 WD40 domain, reminis-
cent of the motif identiﬁed in UNG2 as being necessary for Vpr
interaction (BouHamdan et al., 1998). However, mutation of these
motifs individually failed to identify residues of DCAF1 which
interact with Vpr (Gérard et al., 2014). The generation of a DCAF1–
Vpr co-crystal will be of great interest in order to more clearly
resolve the molecular nature of this interaction and its differences
in comparison to that of the DCAF1–Vpx complex.
Vpr and Vpx interact with DCAF1 in a competitive manner with each
other
The above results indicate that the binding surfaces for Vpx and
Vpr on DCAF1 are at least somewhat different. However, because none
of the WD40 domain point mutants tested disrupted Vpr binding
(data summarized in Table 1), we are unable to discern whether Vpx
and Vpr bind to overlapping or non-overlapping regions on the WD40
domain. To test whether the binding regions may overlap, we
designed the following competition experiment. We hypothesized
that if the Vpr and Vpx binding regions on DCAF1 overlap, then over-
expression of Vpr would to some degree interfere with the ability of
Vpx to recruit SAMHD1 to the ubiquitin ligase complex and would
therefore hinder SAMHD1 degradation. 293FT cells were transfected
with HA-Vpx alone or in combination with HA-Vpr at 1:2 or 1:1 Vpx:
Vpr expression plasmid ratios. As expected, Vpx expression resulted in
the depletion of SAMHD1 (Fig. 6, lane 1 vs. lane 2). Co-expression of
Vpr robustly inhibited Vpx induced SAMHD1 degradation at both
ratios (Fig. 6, lanes 3 and 4 vs. lane 2). Therefore, although we were
unable to deﬁne speciﬁc residues on DCAF1 that mediate interaction
with Vpr, the ability of Vpr to interfere with Vpx function suggest that
both viral proteins bind to overlapping areas within the top face of the
DCAF1 WD40. However, these results, cannot distinguish whether this
competition is for a shared/overlapping binding site of Vpr and Vpx or
if this competition is due to conformational changes in DCAF1 induced
by Vpr binding that may in turn disrupt Vpx binding at a distance.
Based on the high homology between their third α-helices, we favor a
model in which HIV-1 Vpr and SIVmac Vpx utilize a similar, but not
identical, binding interface on DCAF1 (Le Rouzic et al., 2007; Schwefel
et al., 2014; Srivastava et al., 2008) (reviewed in Morellet et al. (2009)).
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Fig. 4. Model of Vpx manipulation of the CRL4DCAF1 ubiquitin ligase. Interaction of
DCAF1 WD40 domain with Vpx is mediated primarily by interactions between
DCAF1 N1135 and W1156 and Vpx (red lines). Interaction between Q76 of Vpx with
residues N1135 and W1156 in DCAF1 was documented by Schwefel et al. (2014). In
addition, mutation of DCAF1 D1092 was observed to disrupt the ability of Vpx to
mediated SAMHD1 degradation without affecting binding to Vpx. D1092 was
recently shown to form an ionic bond with SAMHD1 K622 by Schwefel et al.
(2014) (orange line). Finally, based on previous reports interactions between Vpx
and SAMHD1 are known to involve multiple residues within the unstructured N-
terminus and linker between second and third α-helix of Vpx and SAMHD1 (blue
lines) (Schwefel et al., 2014).
Fig. 5. DCAF1 residues required for Vpr interaction differ from those required for
Vpx interaction. Plasmids expressing FLAG-DCAF1 or mutants and HA-Vpr were
transfected into 293FT cells. FLAG-DCAF1 was then immunoprecipitated and
analyzed for the presence of HA-Vpr by Western blot.
Fig. 6. Vpr is dominant over Vpx mediated SAMHD1 degradation. 293FT cells were
transfected with a HA-Vpx plasmid in the absence or presence of increasing
concentrations of HA-Vpr. All cells were transfected with equal amounts of total
plasmid DNA by transfection of pcDNA3.1. Cells were lysed 36 h post-transfection
and endogenous SAMHD1 levels were analyzed by Western blot.
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Abstract 
Hijacking of the Cullin-RING E3 ubiquitin ldownmodulateigase (CRL) 
machinery is a common mechanism employed by diverse groups of viruses for 
the efficient counteraction and eventual degradation of host proteins. In 
particular, HIV-1 Vpu usurps the Skp1-Cullin1-F-box (SCF) E3 ubiquitin (Ub) 
ligase complex to ubiquitinate CD4 for eventual degradation by the 26S 
proteasome. Vpu also interacts with and downmodulates a number of other host 
proteins, including the restriction factor BST-2. Recent data have suggested a 
model through which Vpu mistrafficks BST-2 via adaptor-protein 1 (AP-1) for 
eventual lysosomal degradation, independently of cullin activity. However, 
whether Vpu primarily relies on a cullin-dependent or -independent mechanism to 
antagonize host proteins in primary CD4+ T cells has not been fully elucidated.  
We utilized a sulphamate AMP analog, MLN4924, to effectively block the 
activation and thus activity of CRLs within infected primary CD4+ T cells. 
MLN4924 treatment, in a dose-dependent manner, efficiently relieved surface 
downmodulation and degradation of CD4 by Vpu. As expected, the drug had no 
effect on Nef’s ability to counteract CD4, which does not rely on CRL activity. 
Interestingly, Vpu’s capacity to downregulate BST-2, NTB-A, and CCR7 was not 
inhibited by MLN4924, suggesting that in primary CD4+ T cells, AP-1-mediated 
mistrafficking, but not b-TrCP-dependent ubiquitination/degradation, is the main 
mechanism of Vpu activity.   
The CRL complexes are an essential component of HIV-1 infection. While 
most accessory genes hijack this machinery to degrade host proteins and evade 
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immune detection, Vpu primarily antagonizes its target proteins via a cullin-
independent mechanism. Therefore, drugs that target a combination of CRLs, 
such as MLN4924, as well as AP-1, may show promise in help promoting anti-
viral defense.  
 
Introduction 
Viruses are intracellular obligate parasites that hijack host cellular 
machinery to promote their efficient replication and dissemination. In particular, a 
recurring theme between diverse species of viruses is their common ability to 
usurp the host cullin-ring finger ubiquitin ligase (CRL) complexes with the aim of 
evading host control mechanisms. Notably, the HIV-1 accessory protein Vif 
hijacks a cullin-5 containing ubiquitin ligase complex (CRL5) to target the cytidine 
deaminase APOBEC3G (A3G) for proteasomal degradation (Marin et al., 2003; 
Mehle et al., 2004a; Mehle et al., 2004b; Sheehy et al., 2002; Yu et al., 2003). In 
the absence of Vif, A3G is incorporated into virions and induces lethal dG to dA 
hypermutation within the viral genome (Harris et al., 2003; Stopak et al., 2003). 
Similarly, the HIV-2 accessory protein Vpx relies on a cullin-4 containing (CRL4) 
complex to degrade the restriction factor SAMHD1, thus preventing a decrease in 
intracellular dNTP levels via SAMHD1’s deoxynucleoside triphosphohydrolase 
activity and allowing for efficient viral DNA synthesis by reverse transcriptase 
(RT) (Baldauf et al., 2012; Hrecka et al., 2011; Laguette et al., 2011; Lahouassa 
et al., 2012). 
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Indeed, cullin activity has also been shown to be an important factor for 
the HIV-1 Vpu protein. Vpu is an 81 amino acid type 1 integral membrane 
phosphoprotein expressed in most isolates of HIV-1, some SIVs such as SIVgsn, 
SIVmon, SIVmus, SIVden, (Strebel, 2014), including the closely related primate 
lentivirus SIVcpz, but not HIV-2 (Cohen et al., 1988; Maldarelli et al., 1993; 
Strebel et al., 1989).  
Translation of Vpu and envelope (Env) occurs from a single bi-cistronic 
mRNA late in the viral life cycle (Schwartz et al., 1990). Biologically, Vpu induces 
the rapid degradation of newly synthesized CD4 within the endoplasmic reticulum 
(ER), relieving the formation of gp160-CD4 complexes in the ER and allowing 
envelope glycoprotein (gp) maturation and full viral assembly (Bour et al., 1991; 
Lenburg and Landau, 1993; Willey et al., 1992a, b). Vpu degradation pf CD4 
requires two highly conserved, constitutively phosphorylated serine residues 
within its cytoplasmic domain that bind the F-box protein substrate receptor 
β-TrCP, which together with the adaptor protein Skp1, recruit a cullin-1 
containing (CRL1) complex to target CD4 for proteasomal degradation (Margottin 
et al., 1998; Schubert et al., 1994; Schubert and Strebel, 1994).  
Vpu is known to antagonize multiple host proteins. In addition to CD4, Vpu 
also counteracts the restriction factor BST-2 (tetherin) via cell surface 
downregulation, thereby increasing viral budding and release (Klimkait et al., 
1990; Neil et al., 2008; Van Damme et al., 2008). Mechanistically, previous 
reports have shown that Vpu can antagonize BST-2 via proteasomal and / or 
β-TrCP and ESCRT-dependent lysosomal degradation (Caillet et al., 2011; 
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Douglas et al., 2009; Goffinet et al., 2009; Gupta et al., 2009; Iwabu et al., 2009; 
Janvier et al., 2011; Mangeat et al., 2009; Mitchell et al., 2009). Additionally, 
others found that sequestration of BST-2 within the trans-golgi network (TGN), 
was important for Vpu antagonism (Dubé et al., 2010; Dube et al., 2009; Vigan 
and Neil, 2010). More recent studies, however, have shown that a putative 
clathrin sorting motif, ExxxLV (ELV), present within the cytoplasmic domain of 
subtype B Vpu, is also critical to counteract BST-2 (Kueck and Neil, 2012). 
Indeed, Jia et al. recently found that the clathrin adaptor-protein-1 (AP-1), a 
molecule involved in the trafficking of cargo between the TGN and sorting 
endosomes, simultaneously binds Vpu via its ELV motif as well as BST-2, 
thereby causing  the mistrafficking of BST-2 away from viral assembly sites for 
eventual lysosomal degradation (Jia et al., 2014). Yet, whether the major 
mechanism of BST-2 counteraction by Vpu primarily involves AP-1-mediated 
mistrafficking or β-TrCP-dependent degradation within primary CD4+ T cells is 
still not fully understood.  
Moreover, other than CD4 and BST-2, Vpu can negatively affect other 
important immune factors, such as NTB-A, CD1d, and CCR7. NTB-A is a co-
activating signal molecule necessary for Natural Killer (NK) degranulation. Thus, 
through downregulation of cell surface NTB-A by Vpu, HIV-1 infected cells 
efficiently evade lysis by NK cells (Shah et al., 2010). Furthermore, 
downregulation of CD1d on HIV-1 infected dendritic cells (DCs), which is a 
coordinated effect of both Nef and Vpu, hinders lipid antigen presentation to 
invariant natural killer T (iNKT) cells (Moll et al., 2010). Finally, our recent studies 
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have shown that the chemokine receptor CCR7 is downmodulated on infected 
primary CD4+ T cells by Vpu, thus impairing their ability to efficiently migrate 
towards a gradient of CCL19 and CCL21 (Ramirez et al., 2014). 
Physiologically, CRLs constitute an important group of ubiquitin ligases 
and play a prominent role in the efficient regulation of protein turnover and 
homeostasis (Petroski and Deshaies, 2005). Their activation is dependent on a 
process known as neddylation. This posttranslational modification involves the 
addition of the NEDD8 protein, a relative of ubiquitin, onto cullins via a lysine 
residue linkage. This posttranslational modification induces a conformational 
change that renders the enzyme catalytically active (Bosu and Kipreos, 2008; 
Hori et al., 1999; Kamitani et al., 1997).  
Indeed, the neddylation pathway, like the NEDD8 protein, occurs in a very 
similar fashion to protein ubiquitination. First, NEDD8 precursor processing 
occurs through a C-terminal hydrolase, followed by activation of Nedd-8 by the 
Nedd8-Activating Enzyme (NAE; E1), a heterodimer of APPBP1 and UBA3, in an 
ATP-dependent manner (Huang et al., 2004). This creates a NEDD8-AMP 
adenylate intermediate, which can then go on to form an NAE-NEDD8 thioester 
(Bohnsack and Haas, 2003; Brownell et al., 2010). Next, NEDD8 is transferred to 
one of two E2 conjugating enzymes, UBE2M (Ubc12) or UBE2F, via a 
transthiolation reaction (Huang et al., 2007; Liakopoulos et al., 1998).  Finally, 
NEDD8 is shuttled to an E3 ligase, which confers substrate specificity. 
In this work, we utilized MLN4924, a potent inhibitor of NAE (Nedd8-
Activating Enzyme, NAE; E1), to selectively block CRL activity and thus 
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determine the necessity for β-TrCP in Vpu antagonism of host proteins 
endogenously expressed within primary CD4+ T cells (Soucy et al., 2009).  Our 
results indicate that CRL activity is absolutely required for Vpu-mediated CD4 cell 
surface downregulation and degradation. However, the ability of Vpu to 
downmodulate BST-2, CCR7, and NTB-A was completely independent of cullin 
activity, further suggesting that mistrafficking of these host proteins, presumably 




Neddylation and Scfβ-Trcp Activity Is Required for Vpu-mediated 
Cell Surface Downregulation of CD4 but Not for BST-2,  
CCR7 or NTB-A downmodulation 
Previous studies involving HIV-1 and the neddylation inhibitor MLN4924 
have shown that the drug can potently block Vif-mediated proteasomal 
degradation of A3G (A3G)(Stanley et al., 2012). In addition, Stanley et al. found 
that knockdown of the neddylation E2 conjugating enzyme UBE2F, but not 
UBE2M (Ubc12), can restore restriction by A3G and circumvent the effects of Vif 
(Stanley et al., 2012). Furthermore, in the context of HIV-2, MLN4924 inhibited 
the degradation of SAMHDI facilitated by Vpx, phenocopying an HIV-2 virus 
lacking the accessory protein and restoring viral restrictive potential in myeloid 
cells (Hofmann et al., 2013; Nekorchuk et al., 2013; Wei et al., 2014).  
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Additionally, MLN4924 inhibited the induction of G2 arrest by HIV-1 Vpr (data not 
shown). 
We therefore wanted to address, in primary CD4+ T cells, whether 
pharmacological inhibition of the SCFβ-TrCP complex by MLN4924 would restore 
surface levels of proteins antagonized by Vpu. We hypothesized that Vpu 
counteraction of CD4, being dependent on β-TrCP and CRL activity, would be 
negatively affected by MLN4924. We also predicted that downregulation of BST-
2, CCR7, and NTB-A, where targeting of the SCFβ-TrCP complex may not be the 
dominant mode of counteraction, would either show an intermediate or no effect 
after drug treatment. To that end, primary CD4+ T cells (generated as described 
in Materials and Methods) were infected with either an HIV-1NL4-3 replication-
defective molecular clone carrying GFP in place of Nef (DHIV GFPΔNef), or as a 
negative control, a virus lacking both Nef and Vpu (DHIV 
GFPΔNefΔVpu)(Ramirez et al., 2014). All viruses were pseudotyped with the 
vesicular stomatitis virus glycoprotein (VSV-G) envelope. Particularly, we utilized 
these viruses because unlike BST-2, CCR7, and NTB-A, where antagonism is 
exclusive to Vpu, CD4 is counteracted by HIV-1 envelope, Nef, and Vpu, thus 
infection of cells with DHIV GFPΔNef pseudotyped with VSV-G would allow us to 
probe the effect of Vpu function only (Malim and Emerman, 2008). Two days post 
infection, cells were incubated in either DMSO or increasing concentrations of 
MLN4924 in DMSO, and then stained for surface proteins and analyzed by flow 
cytometry 24h later. As expected, a virus devoid of Nef and Vpu (DHIV 
GFPΔNefΔVpu) showed similar surface levels of CD4, BST-2, CCR7, and NTB-A 
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between GFP negative and positive cells (Figure 4.1A, panels ii,viii,xiv,xx). 
Furthermore, downregulation of CD4, BST-2, CCR7, and NTB-A was apparent in 
cells that were infected with DHIV GFPΔNef and treated with DMSO only (Figure 
4.1A, panels iii,viv,xv,xxi). However, in a dose-dependent manner, MLN4924 
completely relieved the downmodulation of CD4 mediated by Vpu, indicating that 
CRL activity is essential for Vpu to antagonize CD4 (Figure 4.1A, compare 
panels iii-vi; Figure 4.1B). In contrast, surface levels of BST-2, CCR7, and NTB-A 
were unaffected by MLN4924 treatment, suggesting that recruitment of the SCFβ-
TrCP complex is not the dominant mechanism employed by Vpu to antagonize 
these proteins (Figure 4.1A, panels vii-xxiv; Figure 4.1B). We were unable to 
assess the effect of MLN4924 on the downmodulation of the natural killer cell 
activating ligand CD155 (PVR), which has been shown to be a target of both Nef 
and Vpu, because we were unable to reproduce downregulation of cCD155 after 
infection with DHIV GFPΔNef (data not shown). Thus taken together, these 
results suggest that Vpu utilizes both a cullin-dependent and -independent 
mechanisms for antagonizing host proteins.  
 
MLN4924 Inhibits Vpu-Mediated CD4 Degradation by Blocking  
Neddylation of the Scfβ-Trcp Complex 
 To determine whether MLN4924 prevented the actual degradation of CD4, 
as opposed to just the surface downregulation, primary CD4+ T cells were 
infected as described in Figure 4.1 but were instead permeabilized, fixed, and 
stained for total levels of CD4. Figure 4.2 collectively shows that inhibition of 
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neddylation rescued CD4 from Vpu-mediated degradation in a dose-dependent 
manner that mirrored what we observed at the cell surface (Figure 4.2A; 4.2B, 
left panel). Furthermore, MLN4924 treatment did not have any adverse effects in 
modulating CD4 expression in uninfected (Mock) or DHIV GFPΔNefΔVpu 
infected cells. We did, however, observe that CD4 levels were slightly 
upregulated in GFP positive cells infected with DHIV GFPΔNefΔVpu, a 
phenomenon we and others have observed with other host proteins (Figure 4.2B 
right panel) (Kueck and Neil, 2012).  
  
Nef-Mediated CD4 Antagonism Is Unaffected by MLN4924   
Treatment 
Nef is a 27kDa multifunctional myristoylated protein localized within the 
cytoplasmic side of cellular membranes and expressed early within the HIV-1 
viral life cycle. Nef interferes with a number of cellular trafficking and signaling 
pathways that ultimately lead to increased viral spread and pathogenesis 
(Kirchhoff, 2010). One of Nef’s key functions is the counteraction of CD4. 
However, unlike Vpu, which acts on newly synthesized CD4 molecules within the 
ER, Nef accelerates the endocytosis of target CD4 molecules present on the 
plasma membrane via a clathrin and Adaptor Protein 2 (AP2) pathway (Aiken et 
al., 1994; Chaudhuri et al., 2007; Rhee and Marsh, 1994). Moreover, Nef has 
been shown to shuttle CD4 through a multivesicular body (MVB) pathway that 
involves members of the endosomal sorting complex required for transport 
(ESCRT) machinery, eventually leading to CD4 lysosomal degradation (daSilva 
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et al., 2009). Yet, while accelerated endocytosis and targeting of CD4 through 
the MVB pathway are separate functions of Nef, neither rely on the recruitment of 
CRL complexes. We therefore hypothesized that a virus only encoding Nef would 
be unaffected by MLN4924 treatment in its ability to downregulate CD4. Primary 
CD4+ T cells were infected with either HIV-1 (DHIV WT), a virus lacking Vpu 
(DHIV ΔVpu), or a virus lacking Nef (DHIV ΔNef). As expected, a ΔNef virus was 
unable to cause CD4 downregulation in the presence of MLN4924 (Figure 4.3, 
panel viii). Thus, our data clearly show that inhibiting CRL activity only prevents 
Vpu-mediated CD4 antagonism, but not counteraction by Nef, which is cullin 
independent.   
 
Discussion 
It is now well appreciated that hijacking of CRLs is a common theme for 
many viruses, regardless of their nucleic acid makeup or sense (Mahon et al., 
2014). In particular, the Ad5 Adenovirus strain encodes two viral proteins, 
E4ORF6 and E1B55K, which together activate the CRL5 complex to degrade the 
master cell cycle and apoptosis regulator p53, thereby preventing cell cycle 
arrest and premature apoptosis (Querido et al., 2001a; Querido et al., 2001b). 
Similarly, Kaposi’s sarcoma associated herpesvirus (KSHV) utilizes its virally 
encoded latency-associated nuclear antigen (LANA) protein to target p53 and 
VHL (Von Hippel-Lindau Tumor Supressor) for ubiquitination and subsequent 
proteasomal degradation through a CRL5 complex (Cai et al., 2006). Moreover, 
the Large T antigen (LTAg) of the polyoma virus SV40 has been associated with 
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the ability to bind CRL7, thereby leading to deregulation of its substrate, the 
insulin receptor substrate 1 (IRS-1), possibly to dampen downstream IRS-1 
pathways related to oncogenesis (Kasper et al., 2005). Finally, the Epstein Barr 
Virus (EBV) protein BPLF1 mimics the deneddylase activity of the host COP9 
signalosome (CSN), resulting in the accumulation of CRL substrates and the 
deregulation of the cell cycle, providing a favorable environment for viral DNA 
replication (Gastaldello et al., 2010).  
Despite the requirement for cullin activity in HIV-1 Vif, HIV-2 Vpx, and HIV-
1 Vpr function, the data presented here argue that HIV-1 Vpu targets host 
proteins, with the exception of CD4, through a cullin-independent mechanism.  
Indeed, inhibiting neddylation with MLN4924 clearly did not have any effect on 
restoring Vpu-dependent BST-2 surface levels, even at high concentrations. 
Interestingly, Schindler and colleagues found that endogenous BST-2 levels 
were comparatively lower within CD4+ T cells as opposed to macrophages. 
Consequently, a Vpu mutant unable to bind β-TrCP hindered viral replication and 
counteraction of BST-2 within macrophages, but not within tissue CD4+ T cells 
(Schindler et al., 2010). Our data support a model whereby within CD4+ T cells, 
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Materials and Methods 
Cells and Plasmids 
 Human embryonic kidney 293T (HEK293T) cells were maintained in 
Dulbecco’s Modified Eagles’ Medium (DMEM) containing 10% Fetal Bovine 
Serum (Atlas Biologicals) supplemented with 100 U/ml Penicillin, 100 mg/ml 
Streptomycin, and 2mM L-glutamine (Life Technologies). HeLa-CD4 (obtained 
through the NIH AIDS Reagent Division of AIDS, NIAID, NIH (Cat. #459)) were 
cultured in RPMI complete media in the presence of 1 mg/ml G418 (Life 
Technologies) while CCRF-CEM and primary CD4+ T cells were cultured in RPMI 
complete media only.  All cells were maintained at 5% CO2 at 37°C. For all 
experiments involving primary CD4+ T cells, coverage was maintained under 
protocol #IRB_00067637 approved by the University of Utah Institutional Review 
Board. The generation of cultured TCM has been described previously (Ramirez 
et al; Cell Reports 2014). 
All DHIV plasmids used in this manuscript have been described previously 
(Ramirez et al. 2014). Briefly, the “defective” HIV (DHIV) plasmid, derived from 
the HIVNL4-3 isolate, contains a frame-shift mutation within envelope/gp120 but 
maintains in-frame Tat, Rev and RRE ORFs.  
 
Pharmacological Inhibitor MLN4924 
MLN4924 was purchased from Cayman Biologicals. The dry solvent was 
then resuspended in DMSO at a stock concentration of 20 mM, further aliquotted 
and diluted at 200 mM, and used as indicated.  
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Flow Cytometry Antibodies 
To measure relative surface levels of CD4, BST-2, CCR7, and NTB-A, 
primary CD4+ T cells were stained with the human monoclonal antibodies anti-
APC-CCR7 (Caltag, Burlingame CA), anti-APC-CD4 (Life Technologies), and 
anti-NTB-A (Life Technologies). Surface analysis of BST-2 was determined using 
anti-BST-2 (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH; Drs. 
Klaus Strebel and Amy Andrew (Cat. # 11722)) followed by staining with a goat-
anti-rabbit secondary antibody coupled to Alexa Fluor 647 (Molecular Probes, 
Invitrogen). A viability dye, eFlour 450 (eBioscience), was then used to 
distinguish live from dead cells. Fixation was achieved using .5% 
Paraformaldehyde (PFA). All staining and fixation steps were performed at 4°C 
for 30 minutes in buffer (1x PBS + 3% FBS). Detection of CD4 and BST-2 on the 
surface of HeLa-CD4 was determined as described above.   
In experiments involving surface analysis of CD4 and detection of 
intracellular p24, cells were first probed with anti-APC-CD4, stained with eFluor 
450, permeabilized (Cytofix/Cytoperm;), and then stained with mouse-anti-FITC-
p24 (clone KC57, Beckman Coulter). Total levels of CD4 in primary CD4+ T cells 
were measured by staining cells with eFlour 450, permeabilization, and then 
probing with anti-APC-CD4. All data were collected on a BD FACS Canto and 
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Viruses and Infections 
 Viral stocks were generated by co-transfection of 20 mg DHIV along and 
5mg of a construct expressing vesicular stomatitis virus G-protein (VSV-G) by 
calcium phosphate-mediated transfection into HEK293T cells.  Media (DMEM) 
was replaced after 16 h and the cellular supernatant collected, aliquotted, and 
stored at -80°C 48h post-transfection. Viral titers and MOI were determined via 
infection of CCRF-CEM cells. Primary CD4+ T cells generated as described 
above were infected five days post-activation at an MOI of either 1 (Flow 
Cytometry) or 3 (Immunoblotting) via spinoculation: 106 cells (1 ml final volume) 
for 2h at 37°C in the presence of 8mg/ml Polybrene (Sigma). After infection, cells 
were then resuspended in RPMI complete medium supplemented with IL-2 (30 
U/ml).  
 For infection of HeLa-CD4, 2 x 105 cells were plated in a 6 well plate. 24h 
later, the cells were infected at an MOI = 2 for 5h at 37°C in the presence of 
8mg/ml Polybrene (Sigma). Following infection, the cells were resuspended in 
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Figure 4.1. HIV-1 Vpu utilizes both a cullin-dependent and -independent 
mechanism to antagonize host proteins.  
A. Primary CD4+ T cells were either mock infected or infected at an MOI of 1 with 
DHIVGFPDNef or DHIVGFPDNefDVpu. 2 days post infection, either DMSO or 
increasing concentrations of MLN4924 were added to cell cultures. 24h later, 
surface expression of CD4, BST-2, CCR7, or NTB-A was analyzed by flow 
cytometry. Histograms depict a comparison of GFP negative (blue line) and GFP 
positive (red line) cells along with an IgG matched isotype control (gray shaded 
histogram). Unless otherwise noted, all experiments involving primary CD4+ T 
cells are representative of three distinct experiments performed in three separate 
healthy donors. B. Mean Fluorescence Intensity (MFI) values of surface 
expression of CD4, BST-2, CCR7, or NTB-A from DHIVGFPDNef infected cells 
(A). Data were normalized by setting the MFI values from uninfected (mock) cells 
to 100% and is depicted graphically as +/- SEM.  
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Figure 4.2. MLN4924 inhibits Vpu-mediated degradation of CD4.  
A. Cultured TCM were either mock infected or infected at an MOI of 1 with 
DHIVGFPDNef or DHIVGFPDNefDVpu. 48h after infection, cell cultures were 
treated with either DMSO or increasing concentrations of MLN4924. To assess 
total levels of CD4, cells were permeabilized and stained 24 h after addition of 
MLN4924 and analyzed by flow cytometry. Histograms represent GFP negative 
cells (blue line), GFP positive cells (red line), or an IgG matched isotype (gray-
shaded histogram). B. MFI values of total (intracellular) CD4 expression levels 
from either DHIVGFPDNef (left) or DHIVGFPDNefDVpu (right). Data were 
normalized by setting the MFI values from uninfected (mock) cells to 100% and is 
depicted graphically as +/- SEM.  
 
	   85	  
 
Figure 4.3: Inhibition of CRL activity negatively affects Vpu, but not Nef-mediated 
antagonism of CD4.  
A. Primary CD4+ T cells were either mock infected or infected at an MOI of 1 with 
DHIV WT, DHIVDVpu, or DHIVDNef.  2 days post infection, cell cultures were 
treated with either DMSO or 500 nM MLN4924. To determine the impact of 
MLN4924 treatment on viruses lacking Vpu or Nef, surface levels of CD4 were 
assessed by flow cytometry. Histograms represent GFP negative cells (blue line), 
GFP positive cells (red line), or an IgG matched isotype (gray-shaded histogram). 
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HIV/SIV lentiviruses encode accessory proteins that were shown to 
overcome host restriction factors to favor viral replication. Understanding how 
accessory proteins avoid immune recognition could be used for new drug 
development. Although the mechanisms used by accessory proteins to target 
APOBEC3G, CD4, and SAMHD1 (degraded by Vif, Vpu, and Vpx, respectively) 
are well established, the exact host proteins used by Vpr to induce G2 arrest 
remain unknown.  
Vif degrades APOBE3G by hijacking Cul5 (Sheehy et al., 2003; Yu et al., 
2003); Vpu degrades CD4 through Cul1 (Margottin et al., 1996; Margottin et al., 
1998); Vpx degrades SAMHD1 by associating wth Cul4 via DCAF1 via a direct 
interaction (Hrecka et al., 2011; Laguette et al., 2011). Considering that all these 
accessory proteins usurp the ubiquitin proteasome system (UPS) to degrade a 
specific host factor, and since Vpr interaction with Cul4DDB1/DCAF1 is necessary to 
induce cell cycle arrest (DeHart et al., 2007; Hrecka et al., 2007; Wen et al., 
2007), one hypothesis was that Vpr recruits a host protein to the Cul4 ubiquitin 
E3 ligase for ubiquitination/degradation.  
Recently, it was reported that Vpr targets the SLX4 complex to arrest the 
cell cycle (Laguette et al., 2014). SLX4com contains the endocuclease Mus81, 
which was shown to be ubiquitinated and degraded in the presence of Vpr 
(Laguette et al., 2014). Surprisingly, our results showed that degradation of 
Mus81 is independent of Vpr-induction of G2 arrest. The well-known Vpr point 
mutants (R80A and Q65R), which are unable to arrest cells in G2/M, were found 
in our studies to degrade Mus81. It was demonstrated that Vpr interaction with 
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SLX4 was required for induction of cell cycle arrest (Berger et al., 2014). 
However, ubiquitination of the SLX4com induces its activation but not 
degradation. This result is in contradiction with the current model of activity. 
Indeed, according to the prevailing model, knockdown of the putative target 
would mimic the cell cycle arrest induced by Vpr. However, siRNA depletion of 
each of the SLX4com components inhibited the G2 arrest-induced by Vpr 
(Laguette et al., 2014). 
In our studies, we confirmed the necessity of the C-terminus of Vpr to 
cause cell cycle arrest.  Earlier reports have suggested the requirement of the C-
terminal unstructured region of Vpr to recruit the putative G2 arrest target (DeHart 
et al., 2007; Di Marzio et al., 1995; Le Rouzic et al., 2007). We took advantage of 
the SIVagm Vpr, a subset of primate lentivirus that encode a bifunctional Vpr 
(SIVagm Vpr degrades SAMHD1 and induces G2 arrest) that is species-specific, 
arresting cell cycle in AGM cell but not in human cells (Planelles et al., 1996). 
Using chimeric proteins between HIV-1 Vpr and SIVagm Vpr, transfer of the C-
terminus of HIV-1 Vpr onto SIVagm Vpr conferred upon SIVagm Vpr a de novo 
ability to induce G2 arrest in human cells. Furthermore and in agreement with 
SIVmac Vpx (Ahn et al., 2012; DeLucia et al., 2013), we found that the N-
terminal domain of SIVagm Vpr is required for degradation of agmSAMHD1.  
A more refined study is necessary to answer some unresolved questions: 
Does SLX4 interact with the C-terminal domain of Vpr? Does the interaction 
between SLX4 and Vpr(R80A) lead to SLX4com activation? Does SLX4 
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activation by Vpr result in ATR activation, a hallmark of the G2 arrest-induced by 
Vpr?  
To understand the manipulation of the Cul4-DCAF1 ubiquitin ligase by Vpr 
and its paralog Vpx, we generated several DCAF1 point mutants and truncations 
(Cassiday et al., 2014). Vpr and Vpx are known to interact with DCAF1 through a 
high conserved region found in their 3rd alpha helix (Le Rouzic et al., 2007; Zhao 
et al., 1994). Surprisingly, our results revealed a novel aspect of the interaction of 
Vpr and Vpx with DCAF1. The point mutations N1135A and W1156H in DCAF1 
inhibited the binding of DCAF1 to Vpx but not to Vpr. When we looked at 
SAMHD1 degradation by Vpx in the presence of Vpr, we observed that Vpr was 
able to decrease Vpx function. However, Vpx was not able to compete Vpr’s 
induction of G2 arrest, suggesting that Vpr binds to DCAF1 with higher affinity 
than Vpx (Cassiday et al., 2014). Furthermore, in agreement with a recently 
solved DCAF1-Vpx-SAMHD1 crystal structure (Schwefel et al., 2014), we 
confirmed on a functional level that Vpx-binding to DCAF1 creates a new 
interface that accommodates SAMHD1, which interacts directly with both Vpx 
and DCAF1. 
The activity of cullins is controlled by the conjugation of a ubiquitin-like 
molecule called NEDD8 (Hori et al., 1999; Huang et al., 2009).  A small molecule 
inhibitor of the NEDD8 pathway, MLN4924 (Soucy et al., 2009), was shown to 
suppress the capacity of Vif and Vpx to degrade APOBEC3G (Stanley et al., 
2012) and SAMHD1 (Wei et al., 2014), respectively.  In agreement with the 
findings by Laguette et al., (Laguette et al., 2014), we have shown that MLN4924 
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blocks Mus81 degradation, suggesting the action of a Cullin-based ubiquitin E3 
ligase.  
In the context of MLN4924, we also asked whether this drug would have 
any effect on previously described targets of Vpu. Vpu was shown to 
downregulate a number of cellular host protein such as CD4 (Margottin et al., 
1996; Margottin et al., 1998), NTB-A (Shah et al., 2010), BST-2/Tetherin (Neil et 
al., 2008), and CCR7 (Ramirez et al., 2014). MLN4924 was able to inhibit 
downregulation of CD4 by Vpu but not that of CCR7, BST-2/Tetherin, or NTB-A. 
These results suggest that while Vpu hijacks Cul1 to ubiquitinate and degrade 
CD4, a mechanism independent of cullin is used to antagonize CCR7 and BST-
2/Tetherin and NTB-A.  
An alternative mechanism used by Vpu to downregulate protein 
expression is trans-golgi entrapment. In the absence of Vpu, newly synthesized 
proteins migrate from the ER to the Golgi and then, under normal conditions, 
anterograde trafficking moves them to the cellular membrane (Ramirez et al., 
2014). However, when Vpu is present, it sequesters these proteins in the trans-
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